Benzoyl Peroxide and Electrocautery Skin Inicision to Eradicate Cutibacterium Acnes
The goal of this prospective randomized clinical trial is to investigate the potential synergistic effect of combination of topical benzoyl peroxide and making skin incision with electrocautery on preventing surgical wound contamination from Cutibacterium acnes (C. acnes) in patients undergoing shoulder replacement.
The main question it aims to answer is:
• Will the combined use of topical application of benzoyl peroxide and making skin incision using electrocautery decrease the positive culture rates of C. acnes in the surgical field?
Participants will be asked to apply topical benzoyl peroxide to the shoulder skin prior to their shoulder replacement surgery if they are randomized in the treatment group. The skin incision will be made using electrocautery in both the control and treatment groups. Microbiology swab cultures will be taken during shoulder replacement surgery to compare the positive culture rates for C. acnes between the groups.
Condition: Prosthetic-joint Infection |
Minimum Age: 18 Years
Status: Not yet recruiting |
Phase: Phase 4
First Posted: December 22, 2022 | Last Updated: May 30, 2023
Study Completion Date: August 30, 2024
Learn More
P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris
This is a randomized, multi-center, double-blinded study in subjects with moderate to severe acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2 concentrations of a topical drug in development or a vehicle. Subjects will be treated for up to 12 weeks.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: September 10, 2014 | Last Updated: May 26, 2023
Study Completion Date: August 31, 2015
Learn More
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
Mechanism-based acne treatment for transgender patients receiving testosterone currently does not exist and is an unmet medical need. This study explores clascoterone to treat testosterone induced acne. Many treatments we use to treat acne in females cannot be used in transgender males because they interfere with hormone therapy. Androgens have been associated with the development of acne vulgaris. Recently, a topical androgen receptor inhibitor cream (clascoterone) has been FDA-approved for the treatment of acne. However, clinical trials of clascoterone have excluded participants on exogenous hormones. Clascoterone has been hypothesized to be effective in the treatment of acne in transgender male participants on masculinizing hormone therapy, but it has never been studied or reported in the literature.
Condition: Acne Vulgaris |
Minimum Age: 16 Years
Status: Not yet recruiting |
Phase: Phase 1/Phase 2
First Posted: May 18, 2023 | Last Updated: May 26, 2023
Study Completion Date: June 01, 2024
Learn More
A Study to Evaluate the Efficacy and Safety of Clear Skin Formula on Mitigating Mild to Moderate Non-cystic Acne
The goal of this clinical trial is to compare Clear Skin Fomula Supplement to Placebo in healthy men and women ages 18-40 to mitigate mild to moderate non-cystic acne over the course of 12 weeks. Participants will be asked to take a daily supplement, have photos of their face taken and answer questionnaires related to their acne.
Condition: Non-Cystic Acne |
Minimum Age: 18 Years
Status: Recruiting |
Phase: Not Applicable
First Posted: May 04, 2023 | Last Updated: May 19, 2023
Study Completion Date: May 31, 2024
Learn More
An Investigation of a Multi-Function Skincare Product to Improve Aging, Eczema, and Acne Outcomes
For the skin to function optimally, it needs to be nourished and supplied with the necessary compounds to support health. However, many individuals are deficient in those compounds, leading to negative skin outcomes. Most products on the market today only supply one or two compounds that can benefit skin health. Hemptress has developed a multi-function oil designed to help with outcomes related to acne, aging, and eczema, among others.
This twelve-week trial will examine the effectiveness of Hemptress' test product. This study will be a two-group trial with 45 participants per group. One group will focus on understanding the test product's effects on skin aging symptoms. The other group will focus on understanding the test product's effects on acne and eczema. The trial will be hybrid, and the participants will follow the use instructions provided by the research team.
Condition: Acne, Eczema, Skin Aging |
Minimum Age: 21 Years
Status: Not yet recruiting |
Phase: Not Applicable
First Posted: May 16, 2023 | Last Updated: May 16, 2023
Study Completion Date: November 01, 2023
Learn More
A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption
This randomized, controlled, phase II clinical study is designed to assess the efficacy of preemptive treatment with topical steroids in preventing the papulopustular eruption induced by epidermal growth factor receptor inhibitor (EGFRI) treatment in cancer patients. Participants will be followed up for 6 weeks of twice daily application of triamcinolone cream to the face, chest, and back.
Condition: Acneiform Rash, Papulopustular Eruption |
Minimum Age: 18 Years
Status: Terminated |
Phase: Phase 2
First Posted: February 15, 2017 | Last Updated: May 13, 2023
Study Completion Date: September 02, 2022
Learn More
Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris
The goal of this study is to determine if topical tranexamic acid is capable of decreasing the pigment of the dark spots left from acne bumps. The first line medication used for this often is not tolerated well by patients, and topical tranexamic acid has minimal reported side effects thus far.
Condition: Postinflammatory Hyperpigmentation |
Minimum Age: 18 Years
Status: Withdrawn |
Phase: Phase 2/Phase 3
First Posted: November 17, 2017 | Last Updated: May 12, 2023
Study Completion Date: January 09, 2022
Learn More
P3 Long Term Safety Study of Once Daily SB204 in Acne
This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: June 09, 2016 | Last Updated: May 10, 2023
Study Completion Date: April 27, 2017
Learn More
LiftActiv B3 in Post Inflammatory Hyperpigmentation (PIHP)
The purpose of this research study is to measure the depigmenting effect of a serum product called Liftactiv B3 in patients with mild to moderate facial PIHP (Post Inflammatory Hyper Pigmentation)
Condition: Acne, Post Inflammatory Hyperpigmentation |
Minimum Age: 18 Years
Status: Terminated |
Phase: Phase 2
First Posted: March 14, 2022 | Last Updated: May 02, 2023
Study Completion Date: March 06, 2023
Learn More
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Active, not recruiting |
Phase: Phase 3
First Posted: September 19, 2022 | Last Updated: May 01, 2023
Study Completion Date: July 30, 2023
Learn More
Safety and Efficacy of Radio Frequency for the Treatment of Mild to Severe Inflammatory Acne
The aim of this trial is to evaluate the safety and efficacy of the InMode RF Pro System with the Morpheus8 face tip (24 pins) applicator for the treatment of mild, moderate and severe, facial acne vulgaris
Condition: Inflammatory Acne Vulgaris |
Minimum Age: 16 Years
Status: Not yet recruiting |
Phase: Not Applicable
First Posted: April 13, 2023 | Last Updated: April 25, 2023
Study Completion Date: May 01, 2026
Learn More
Clinical Evaluation of the Safety and Performance of FRF for the Treatment and Reduction of Acne Scarring
Prospective, single centre, evaluator-blind study of the safety and performance of fractional radiofrequency (RF) for the treatment and reduction of acne scarring. The study will evaluate the progress of 20 subjects requesting treatment of acne scarring. The study will involve three treatments on both sides of the face with 3-5 week intervals between each treatment. Subjects will be followed at 6 and 12 weeks after their last treatment. Analysis will be performed on all subjects who receive at least one treatment.
Condition: Acne Scars - Mixed Atrophic and Hypertrophic |
Minimum Age: 22 Years
Status: Completed |
Phase: Not Applicable
First Posted: March 29, 2021 | Last Updated: April 24, 2023
Study Completion Date: June 13, 2022
Learn More
Laser Treatment of Moderate to Severe Acne Vulgaris
In this study, we are enrolling subjects with moderate to severe acne vulgaris and investigating the use of a commercially available laser in treating acne.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Active, not recruiting |
Phase: Not Applicable
First Posted: July 02, 2020 | Last Updated: April 21, 2023
Study Completion Date: December 31, 2023
Learn More
Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.
Condition: Acne Vulgaris |
Minimum Age: 17 Years
Status: Active, not recruiting |
Phase: Phase 4
First Posted: April 20, 2021 | Last Updated: April 21, 2023
Study Completion Date: May 15, 2023
Learn More
Fractional Radiofrequency for Treatment of Acne Scars and Wrinkles
This study will evaluate the clinical efficacy, safety and the performance of the fractional radiofrequency delivered by the BTL-585-4 applicator of the BTL-585F system for non-invasive treatment of acne scars and facial wrinkles. The study is a prospective multicenter open label two-arm study. The subjects will be enrolled and assigned into two study groups, according to their indication; group A (acne scars) and B (facial wrinkles), each study group will receive treatment of different conditions. Subjects of both groups will be required to complete three (3) treatment visits and two to three follow-up visits.
Condition: Acne, Wrinkle |
Minimum Age: 21 Years
Status: Completed |
Phase: Not Applicable
First Posted: April 12, 2023 | Last Updated: April 12, 2023
Study Completion Date: December 10, 2021
Learn More
Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring
To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin Nectar with TriHex Technology®) in wound healing and scar reduction following Erbium:YAG hybrid resurfacing laser for acne scarring compared to the standard of post-procedure care consisting of a bland moisturizer.
Condition: Acne Scars - Mixed Atrophic and Hypertrophic |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: October 21, 2020 | Last Updated: April 11, 2023
Study Completion Date: June 18, 2021
Learn More
P3 Study in Acne Comparing Once Daily SB204 and Vehicle
This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: February 01, 2016 | Last Updated: April 10, 2023
Study Completion Date: December 21, 2016
Learn More
Efficacy of Surgical Diathermy in Eradicating Cutibacterium Acnes From Surgical Skin Incision During Shoulder Arthroplasty
Periprosthetic infection following shoulder arthroplasty is a devastating complication. Diagnosing and treating periprosthetic shoulder infection poses a significant challenge. At the forefront of this issue is Cutibacterium acnes because the current prophylactic regimens are insufficient to eradicate C acnes from the surgical field. It is believed that C acnes infections occur during surgery when the sebaceous glands in the skin are cut and exposed, leading to C acnes contaminating the surgeon's instruments and gloves and, thus, the surgical wound. The purpose of this study is to examine if making skin incisions using electrocautery will result in decreased C acnes contamination during shoulder arthroplasty. To this end, we propose a randomized clinical trial where patients undergoing shoulder arthroplasty are randomized into two groups - Electrocautery incision group (Electro) vs. Scalpel incision group (Scalpel) - and swab cultures are obtained from the skin incision and operating surgeon's gloves and forceps
Condition: Infection, Bacterial |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: October 25, 2020 | Last Updated: April 10, 2023
Study Completion Date: December 01, 2022
Learn More
Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement
Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.
Condition: Acne Scars - Mixed Atrophic and Hypertrophic |
Minimum Age: 22 Years
Status: Recruiting |
Phase: Not Applicable
First Posted: April 27, 2022 | Last Updated: April 10, 2023
Study Completion Date: September 10, 2023
Learn More
Experience With Topical Acne Treatment
Acne is a chronic condition that typically requires the use of multiple medications.1 Medication adherence is especially challenging for patients with chronic diseases and often decreases over time, especially for those using topical medications.1 Nonadherence can result in multiple negative effects including treatment failure, increased healthcare costs, and decreased quality of life. Primary nonadherence refers to problems acquiring and starting treatment. Challenges to this form of nonadherence include a lack of knowledge, misunderstanding of usage, poor communication with provider, increased cost, and fear of side effects.2 Secondary nonadherence refers to when the patient does not use the medication as prescribed. Hurdles to secondary nonadherence include delayed results, increased complexity of treatment plan, adverse effects, busy lifestyle, and inconvenience.2
Condition: Acne |
Minimum Age: 18 Years
Status: Not yet recruiting |
Phase: Early Phase 1
First Posted: October 10, 2022 | Last Updated: April 03, 2023
Study Completion Date: June 30, 2024
Learn More
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe Acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 16 Years
Status: Recruiting |
Phase: Phase 2
First Posted: September 09, 2021 | Last Updated: March 30, 2023
Study Completion Date: March 31, 2024
Learn More
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions
Condition: EGFRI Induced Acneiform Lesions |
Minimum Age: 18 Years
Status: Recruiting |
Phase: Phase 2
First Posted: February 10, 2021 | Last Updated: March 26, 2023
Study Completion Date: May 31, 2024
Learn More
Clinical Study to Evaluate Alexandrite Laser for the Treatment of Acne Scars
The intended use of the Alexandrite laser device used in this study is to assess the efficacy and safety of the Alexandrite laser device for the treatment of acne scars on skin types V and VI.
Condition: Acne Scars |
Minimum Age: 18 Years
Status: Recruiting |
Phase: Not Applicable
First Posted: March 11, 2021 | Last Updated: March 16, 2023
Study Completion Date: May 31, 2023
Learn More
Subantimicrobial Doxycycline in Acne
Antibiotic resistance is a public health problem that worsens the more physicians prescribe standard dose antibiotics for acne. Regardless of race, acne vulgaris is one of the most common dermatologic conditions among pediatric populations. As such, clinicians can make a large impact by practicing good antibiotic stewardship while still addressing the impact of acne on adolescents' self-esteem. Subantimicrobial doxycycline maintains its anti-inflammatory effects while eliminating antimicrobial properties and associated risks of drug resistance. Few studies, focused primarily on adults, have shown that subantimicrobial doxycycline is efficacious in treating acne from a physician standpoint. The investigators aim to investigate the patient experience of acne treatment with subantimicrobial dose doxycycline in the pediatric population.
Condition: Acne Vulgaris, Pediatrics |
Minimum Age: 13 Years
Status: Completed |
Phase: Phase 4
First Posted: May 26, 2022 | Last Updated: March 07, 2023
Study Completion Date: November 08, 2021
Learn More
Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris
study designed to assess the safety, tolerability, and efficacy of IDP-120 Gel and IDP-120 Vehicle Gel
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: September 05, 2018 | Last Updated: March 03, 2023
Study Completion Date: March 23, 2020
Learn More
Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris
study designed to assess the safety, tolerability, and efficacy of IDP-120 Gel and IDP-120 Vehicle Gel
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: September 06, 2018 | Last Updated: March 03, 2023
Study Completion Date: May 07, 2020
Learn More
Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne
The main purpose of this study is to assess preliminary efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne and to determine if LYS006 has an adequate clinical profile for further clinical development.
Condition: Inflammatory Acne |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: April 06, 2018 | Last Updated: February 21, 2023
Study Completion Date: March 09, 2022
Learn More
Effect of Subcision and Suction on Acne Scars
The primary objective of this study is to determine whether the use of standard treatment in conjunction with suction will improve acne scars compared to a standard treatment alone.
Condition: Acne Scars |
Minimum Age: 18 Years
Status: Active, not recruiting |
Phase: Not Applicable
First Posted: September 14, 2012 | Last Updated: February 17, 2023
Study Completion Date: December 31, 2023
Learn More
A Pilot Study Testing Fractional Radiofrequency Versus Fractional Photothermolysis for the Treatment of Acne Scars
The purpose of this study is to compare the effectiveness of the ePrime fractional radiofrequency system to the 1550-nm fractional photothermolysis system (Fraxel) in the ability to improve acne scar appearance.
Condition: Cicatrix |
Minimum Age: 18 Years
Status: Active, not recruiting |
Phase: Not Applicable
First Posted: October 15, 2013 | Last Updated: February 17, 2023
Study Completion Date: December 31, 2023
Learn More
Effect of Multiple Subcisions on Rolling Acne Scars
The purpose of this study is to find out whether the use of multiple subcisions over several visits will improve the appearance of rolling acne scars compared to no treatment.
This study was a pilot study designed to determine feasibility of this procedure.
Condition: Acne Scars |
Minimum Age: 18 Years
Status: Active, not recruiting |
Phase: Not Applicable
First Posted: August 12, 2014 | Last Updated: February 17, 2023
Study Completion Date: December 31, 2023
Learn More
Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
The goal of this clinical trial is to learn about HT-001 Topical Gel for treatment of EGFR inhibitor-induced skin toxicities. The main questions it aims to answer are:
Determine the therapeutic effect of HT-001 for treatment of patients who develop acneiform rash undergoing Epidermal Growth Factor inhibitor (EGFRI) therapy using the acneiform rash investigator's global assessment scale [ARIGA]
Evaluate the safety of HT-001 during treatment
Participants will apply HT-001 Gel once per day for 6 weeks, during which the effect on treating acneiform rash or other skin disorders induced by EGFRI therapy will be evaluated using different assessment tools to measure severity of rash, pain, and itching (pruritus), as well as the change in quality of life.
The study will be completed in 2 periods: the first period is open-label (unblinded) and all patients will receive HT-001 topical gel with the active ingredient; the second period is blinded and patients will be randomized to receive one of three concentrations of HT-001 or placebo.
Researchers will compare HT-001 to the placebo in the second period to see if HT-001 provides a significant treatment effect.
Condition: Acneiform Eruption Due to Chemical, Paronychia, Xerosis Cutis |
Minimum Age: 18 Years
Status: Recruiting |
Phase: Phase 2
First Posted: November 14, 2022 | Last Updated: February 13, 2023
Study Completion Date: January 29, 2025
Learn More
Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus
Demonstrate the safety and efficacy of the GentleMax Pro Plus™ laser system for its intended uses: hair removal including pseudofolliculitis barbae (PFB), clearance of pigmented and/or vascular lesions, temporary increase of clear nail in patients with onychomycosis and improvement in appearance of wrinkles. Evaluate GentleMax Pro Plus™ laser system for the clearance of acne.
Condition: Acne, Onychomycosis, Pigmented Lesions, Pseudofolliculitis Barbae, Unwanted Hair, Vascular Lesion, Wrinkle |
Minimum Age: 18 Years
Status: Active, not recruiting |
Phase: Not Applicable
First Posted: July 19, 2021 | Last Updated: February 08, 2023
Study Completion Date: September 30, 2023
Learn More
Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring
This single-center, clinical trial consists of a one autologous fat grafting treatment followed by 3-month and 6-month post-treatment visits in order to assess the efficacy of fat grafting when used by men and women with facial acne scars.
Condition: Acne, Acne Scars - Mixed Atrophic and Hypertrophic |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: September 01, 2020 | Last Updated: January 31, 2023
Study Completion Date: December 14, 2022
Learn More
Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne
The purpose of the study is to assess the safety and efficacy of Arazlo Lotion (Tazarotene 0.045% Lotion) for treatment of postinflammatory erythema and postinflammatory hyperpigmentation in subjects with acne.
Condition: Acne Vulgaris, Erythema, Post Inflammatory Hyperpigmentation, Post Inflammatory Pigmentation Change, Skin Scarring |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: February 05, 2021 | Last Updated: January 19, 2023
Study Completion Date: May 01, 2022
Learn More
Straberi Microneedling For Atrophic Acne
This pilot study will expand knowledge and application needling using the Straberi microneedling device for the improvement of Atrophic Acne Scarring
Condition: Atrophic Acne Scar |
Minimum Age: 21 Years
Status: Recruiting |
Phase: Not Applicable
First Posted: September 13, 2020 | Last Updated: January 17, 2023
Study Completion Date: June 02, 2023
Learn More
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period. All eligible participants will be invited to continue treatment for an additional 48-week Long-term extension period (also open label).
Condition: Acne Inversa, Hidradenitis Suppurativa |
Minimum Age: 18 Years
Status: Active, not recruiting |
Phase: Phase 2
First Posted: July 15, 2020 | Last Updated: January 10, 2023
Study Completion Date: August 16, 2023
Learn More
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
The purpose of this study is to evaluate the efficacy and safety of Trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle cream in the treatment of moderate acne vulagris with risk of acne-induced post inflammatory hyperpigmentation (PIH) after 24 weeks of treatment in facial acne participants
Condition: Acne Vulgaris |
Minimum Age: 13 Years
Status: Completed |
Phase: Phase 4
First Posted: October 11, 2021 | Last Updated: December 19, 2022
Study Completion Date: December 15, 2022
Learn More
Profiling the Skin Microbiome in Response to Altreno in Acne Patients
The study objective is to characterize the shift in the diversity and abundance of the skin microbial community at baseline and in response to Altreno monotherapy as compared to benzoyl peroxide (BPO) 2.5% leave-on gel monotherapy in acne patients.
Condition: Acne, Healthy |
Minimum Age: 18 Years
Status: Active, not recruiting |
Phase: Phase 4
First Posted: July 20, 2020 | Last Updated: December 14, 2022
Study Completion Date: March 31, 2023
Learn More
A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash
Efficacy and Safety of imsidolimab in participants with epidermal growth factor receptor inhibitor (EGFRi)/mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor (MEKi)-associated acneiform Rash
Condition: Acneiform Eruptions |
Minimum Age: 18 Years
Status: Terminated |
Phase: Phase 2
First Posted: December 23, 2020 | Last Updated: December 14, 2022
Study Completion Date: December 13, 2021
Learn More
Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients
The impact of tailored patient-provider communication to improve clinical trial recruitment, patient knowledge, and patient engagement will be studied. Tailored patient-provider communication refers to the individualization of patient-provider communication using patients' preferred methods of communication. This involves the utilization of social messaging such as e-mail or text and/or social media platforms. These communication methods purport to and meet individual patient needs whilst ensuring that information is received and in a format that is familiar to each patient. The primary outcomes of the proposed research is to evaluate the impact of tailored patient-provider communication on patient response rates (speed and number), clinical trial recruitment rates, patient knowledge, and patient engagement.
Condition: Acne, Atopic Dermatitis, Psoriasis |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: November 06, 2020 | Last Updated: December 13, 2022
Study Completion Date: January 19, 2022
Learn More
DMT310-005 Topical in the Treatment of Acne Rosacea
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne rosacea.
Condition: Acne Rosacea |
Minimum Age: 18 Years
Status: Active, not recruiting |
Phase: Phase 2
First Posted: October 26, 2021 | Last Updated: December 07, 2022
Study Completion Date: December 31, 2022
Learn More
Lipidome and Microbiome Profile of Acne
Lipidome and microbiome analysis in subjects with acne on doxycycline. Investigators will look at the skin lipidome, blood lipidome, gut micro biome and skin micro biome.
Investigators will look at the changes between acne subjects and control participants, but also the changes that occur after the use of antibiotics and how this is altered.
Condition: Acne Vulgaris |
Minimum Age: 15 Years
Status: Active, not recruiting |
Phase: Phase 1/Phase 2
First Posted: March 02, 2016 | Last Updated: November 23, 2022
Study Completion Date: January 31, 2027
Learn More
A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants
The purpose of this study is to evaluate the efficacy and tolerance of a gentle facial cleanser in participants with sensitive skin (eczema/atopic dermatitis, rosacea, acne, cosmetic intolerance syndrome).
Condition: Acne Vulgaris, Dermatitis, Atopic, Rosacea, Sensitive Skin |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: October 13, 2021 | Last Updated: November 18, 2022
Study Completion Date: November 30, 2021
Learn More
A Treatment for Severe Inflammatory Acne Subjects
Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules or cysts (non-nodulocystic) during a 12-week treatment period.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: September 08, 2016 | Last Updated: November 14, 2022
Study Completion Date: June 27, 2017
Learn More
Duobrii Treatment of Acne Keloidalis Nuchae (AKN)
Acne keloidalis nuchae (AKN) is one of the chronic forms of scarring folliculitis, affecting predominantly the occipital scalp, seen mostly in men of African descent. Duobrii has the advantage of being the only high potency topical steroid-retinoid combination approved by the FDA with dermatologic indication. Researchers are proposing the off-labeled use of Duobrii for the management of early-mild AKN. The research team hypothesizes that subjects will experience significant clinical improvement in lesion counts. Patients will be followed with visits scheduled at baseline, 4 weeks, 8 weeks, and 12 weeks. During these in-clinic visits, there will be surveys regarding the severity of AKN symptoms, photographs, and clinical assessments.
Condition: Acne Keloidalis Nuchae, AKN |
Minimum Age: 18 Years
Status: Recruiting |
Phase: Phase 3
First Posted: November 01, 2022 | Last Updated: November 01, 2022
Study Completion Date: October 31, 2023
Learn More
The MIRIA Acne Scar Study
This study is being conducted to evaluate the performance and efficacy of the AVAVA MIRIA Laser Skin System treatment on acne scars. Participants will be treated with the MIRIA laser at least 4 times with each treatment spaced 4-6 weeks apart. The improvement of acne scars will be evaluated at 1 month and 3 months with a possibility of 6 months evaluation after the fourth treatment.
Condition: Acne Scars - Mixed Atrophic and Hypertrophic |
Minimum Age: 18 Years
Status: Recruiting |
Phase: Not Applicable
First Posted: October 24, 2022 | Last Updated: October 31, 2022
Study Completion Date: December 31, 2023
Learn More
Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)
Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa
Condition: Acne Inversa, Hidradenitis Suppurativa |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: February 22, 2019 | Last Updated: October 27, 2022
Study Completion Date: March 09, 2021
Learn More
Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne
Acne is common illness of adolescents and young adults which is associated with substantial morbidity. While topical treatments are often sufficient for mild acne, moderate to severe acne often requires treatment with systemic medications such as oral antibiotics, hormonal therapies such spironolactone, and isotretinoin. Sebum overproduction is fundamental to the pathogenesis of acne with associated disordered keratinization and subsequent microbial colonization and inflammation resulting in the clinical manifestations of acne. Given the influence of hormones on sebum production, therapies that address these underlying hormonal factors such as spironolactone and oral contraceptive pills represent an underutilized treatment option for women with acne and could help decrease the use of long-term oral antibiotics in this patient population. The purpose of this trial is to evaluate the comparative effectiveness of spironolactone versus doxycycline hyclate (tetracycline class antibiotic) for women with acne.
Condition: Acne |
Minimum Age: 16 Years
Status: Recruiting |
Phase: Phase 4
First Posted: September 30, 2020 | Last Updated: October 24, 2022
Study Completion Date: July 31, 2026
Learn More
Optical Clearing of the Skin in Conjunction With Laser Treatments
The research hypothesis is that topical application of a mixture of pre-polymers of polypropylene glycol and polyethylene glycol (an optical clearing agent) will reduce skin light scattering, increasing the amount of light reaching the target for diagnostic as well as therapeutic purposes.
Condition: Acne, Hypertrichosis, Nevus of Ota, Port Wine Stain, Scars, Sebaceous Gland Diseases, Tattoos |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: December 18, 2007 | Last Updated: October 19, 2022
Study Completion Date: July 31, 2008
Learn More
Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel
The safety and efficacy of once daily application of IDP 126 Gel will be compared to Epiduo® Forte and IDP-126 Vehicle Gel.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: May 14, 2021 | Last Updated: October 14, 2022
Study Completion Date: September 28, 2022
Learn More
An Exploratory Investigation of a Male Focused Skincare Supplement
Most skincare products on the market are topical and do not take a holistic approach to understanding skin health. This trial will examine a dietary supplement designed to support the gut microbiome and promote skin health from an internal perspective. Research has previously supported the link between the gut microbiome and skin health and the supplement tested in this trial will further the knowledge on the effectiveness of supporting gut health to improve skin outcomes.
Condition: Acne, Skin Abnormalities |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: March 31, 2022 | Last Updated: September 22, 2022
Study Completion Date: June 30, 2022
Learn More
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Acne Vulgaris
Efficacy and Safety of Imsidolimab in Subjects with Acne Vulgaris
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: April 20, 2021 | Last Updated: September 19, 2022
Study Completion Date: March 29, 2022
Learn More
A Study of a Hydrocolloid Bandage on Pimples
The purpose of this study is to evaluate the effectiveness and tolerability of a hydrocolloid bandage on pimples when used overnight for one week.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 1
First Posted: July 19, 2021 | Last Updated: September 13, 2022
Study Completion Date: September 13, 2021
Learn More
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
The purpose of this study is to evaluate the patient-reported outcomes (PROs) in terms of health-related quality of life (HRQoL) and signs of Acne Vulgaris (AV) among patients with moderate to severe non-nodular AV who are administered sarecycline (Seysara®) in real-world community practice settings in the United States (U.S). Investigator's Global Assessment (IGA) of AV and safety measures associated with use of sarecycline (Seysara®) will be assessed over the study observation period of 12 weeks. Clinicians will prescribe sarecycline (Seyara®) as per their own clinical judgment and standard practice.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase:
First Posted: March 25, 2021 | Last Updated: September 12, 2022
Study Completion Date: May 04, 2022
Learn More
Post Market Usability Evaluation Of The PicoSure Pro Device
The intended use of the PicoSure and PicoSure Pro devices used in this study is to treat additional patients with the new PicoSure Pro device and collect additional data on the devices.
Condition: Acne Scars, Benign Dermal Pigmented Lesions, Benign Epidermal Pigmented Lesions, Tattoo Removal, Wrinkle |
Minimum Age: 18 Years
Status: Active, not recruiting |
Phase: Not Applicable
First Posted: October 25, 2021 | Last Updated: September 09, 2022
Study Completion Date: May 31, 2023
Learn More
An Exploratory Investigation of a Novel Skincare Regimen
This trial will assess the effectiveness of the Aria Trio Complete Facial system in being able to reduce blemishes, lines, and wrinkles. This skincare system that has three different functions in association with three unique serums. It is hypothesized that this customized skincare system will improve skin quality, reduce wrinkles, and reduce other skin related issues.
Condition: Acne, Photoaging, Skin Inflammation, Wrinkle |
Minimum Age: 25 Years
Status: Completed |
Phase: Not Applicable
First Posted: August 24, 2022 | Last Updated: August 24, 2022
Study Completion Date: July 01, 2022
Learn More
Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris
The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2/Phase 3
First Posted: July 08, 2016 | Last Updated: August 23, 2022
Study Completion Date: July 19, 2017
Learn More
Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%
The primary objective of this study is to investigate potential differences in treatment adherence by teenagers among four interventions during treatment for acne.
Condition: Acne |
Minimum Age: 13 Years
Status: Completed |
Phase: Phase 4
First Posted: February 16, 2007 | Last Updated: July 28, 2022
Study Completion Date: June 30, 2007
Learn More
Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne
To determine the efficacy and safety of 12 weeks of treatment with Differin Gel, 0.1% compared to 12 weeks of treatment with Tazorac Cream, 0.1% and compared to 6 weeks treatment with Differin Gel, 0.1% followed by 6 weeks of treatment with Tazorac Cream
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: May 02, 2007 | Last Updated: July 28, 2022
Study Completion Date: September 30, 2006
Learn More
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
This study is to determine the efficacy and safety of 12 week treatment with Differin® Gel 0.3% applied in the evening, in combination with Duac® (Clindamycin/Benzoyl Peroxide Gel) applied in the morning, in Subjects with Acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: April 30, 2008 | Last Updated: July 28, 2022
Study Completion Date: August 31, 2008
Learn More
Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes
The purpose of this study is to evaluate the effectiveness of Epiduo® Gel in reducing antibiotic sensitive and resistant strains of P acnes in vivo.
Condition: P Acnes Colonization |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: May 20, 2009 | Last Updated: July 28, 2022
Study Completion Date: July 31, 2009
Learn More
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris
The purpose of this study is to assess subjects' experiences using Adapalene BPO gel to treat mild to moderate acne vulgaris using efficacy measurements, quality of life instruments, and video diaries.
Condition: Acne Vulgaris |
Minimum Age: 16 Years
Status: Completed |
Phase: Phase 4
First Posted: September 24, 2010 | Last Updated: July 28, 2022
Study Completion Date: January 31, 2011
Learn More
Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel
To compare the tolerability of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% to Retin-A Micro® (tretinoin gel) microsphere when used by subjects with acne vulgaris for 3 weeks in terms of local tolerability parameters (erythema, dryness, scaling, stinging/burning) and preference.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: January 23, 2012 | Last Updated: July 28, 2022
Study Completion Date: May 31, 2012
Learn More
Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin.
The purpose of this study is to determine the tolerability of Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30 in pediatric subjects (7-11) with acne prone skin.
Condition: Acne Prone Skin |
Minimum Age: 7 Years
Status: Completed |
Phase: Phase 4
First Posted: July 01, 2013 | Last Updated: July 28, 2022
Study Completion Date: June 30, 2013
Learn More
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
This is an open-label, multi-center study to be conducted in the United States. The study will examine the change in lesion count in subjects using Epiduo® Gel Pump (once daily) in conjunction with Cetaphil® DermaControl™ Foam Wash (twice daily) and Moisturizer SPF 30 (once daily). Subjects with a clinical diagnosis of mild or moderate acne who are eligible for treatment with Epiduo® in accordance with the currently approved product labeling and who meet other inclusion/exclusion criteria are to be enrolled in the study and receive the study products for 8 weeks. Efficacy and safety assessments include: complete lesion counts, cutaneous irritation assessment, end of study treatment questionnaire, photographic evaluation for oiliness, skin tone, and P Acnes, hydration assessment, barrier function assessment, treatment compliance, and adverse event assessment.
Condition: Acne |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 4
First Posted: September 23, 2013 | Last Updated: July 28, 2022
Study Completion Date: March 31, 2014
Learn More
A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris
The goal of this study is to evaluate a complete topical acne regimen consisting of a prescription acne medication (Epiduo® Gel) and an acne-specific cleanser (Cetaphil® DermaControl™ Foam Wash) and moisturizer with sunscreen (Cetaphil® DermaControl™ Moisturizer SPF 30) for safety, efficacy and patient satisfaction in student athletes with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: September 23, 2014 | Last Updated: July 28, 2022
Study Completion Date: February 28, 2015
Learn More
Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa
Hidradenitis suppurativa is a disease involving skin folds, causing swelling of the skin and surrounding tissues, pain, and foul-smelling discharges. Effective treatment options are lacking. Recently, clinical trials conducted in our lab found Brodalumab was an effective drug for this disease. Weekly dosing achieved superior therapeutic outcomes compared to a dosing given once in every other week. Brodalumab was safe in both regimens, but blood and tissue studies to better understand this response are still needed. By performing this small pilot study and collecting blood and tissue samples from participants treated with Brodalumab once weekly we would like to better characterize the molecular response to this treatment, identify blood and tissue markers reflecting disease severity, and better understand disease mechanisms.
Condition: Acne Inversa, Hidradenitis Suppurativa |
Minimum Age: 18 Years
Status: Completed |
Phase: Early Phase 1
First Posted: July 09, 2021 | Last Updated: July 26, 2022
Study Completion Date: July 25, 2022
Learn More
Wound Etiology and Healing Study
The purpose of the WE-HEAL Study is to help researchers use human tissue samples and health records to study the reasons why some patients heal quickly and some have problems healing wounds. All patients seen with an open wound or hidradenitis suppurativa are invited to participate. Information from this research may help to understand how to prevent and treat certain diseases.
Condition: Acne Inversa, Hidradenitis, Hidradenitis Suppurativa, Wounds |
Minimum Age: 18 Years
Status: Completed |
Phase:
First Posted: May 10, 2011 | Last Updated: July 25, 2022
Study Completion Date: January 31, 2022
Learn More
Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device
The intended use of the Potenza™ device is to collect clinical data for brow lifting and/or treatment of dermatologic conditions in which electrocoagulation and hemostasis is a viable mechanism for means of improvement.
Condition: Acne Scars, Active Acne, Crepey Skin, Enlarged Pores, Fine Lines, Loose Skin, Wrinkles |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: February 15, 2022 | Last Updated: July 19, 2022
Study Completion Date: May 17, 2022
Learn More
A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa
This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.
Condition: Acne Inversa |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: September 15, 2019 | Last Updated: July 10, 2022
Study Completion Date: January 10, 2022
Learn More
Investigation of the Tolerability of Two Facial Cleansing Routines for Mild to Moderate Acne
The objective of this study is to compare tolerability of two similar commercially available over the counter acne regimens (Geologie and Proactiv) in individuals with mild to moderate acne vulgaris over a 12-week daily treatment course.
Condition: Acne |
Minimum Age: 18 Years
Status: Recruiting |
Phase: Phase 4
First Posted: June 30, 2022 | Last Updated: July 06, 2022
Study Completion Date: December 31, 2023
Learn More
Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color
Acne vulgaris is a common skin disease characterized by inflammatory papules, pustules, and comedones that is prevalent in men and women of color. Research has demonstrated that Aczone ® (dapsone) gel, 7.5% used once daily is effective, safe, and well-tolerated for the treatment of acne in both men and women; however, limited data is available regarding its efficacy and safety in skin of color (SOC). The current study aims to investigate the therapeutic impact of Aczone gel 7.5% in SOC males and females ages 18 and older with acne vulgaris. The study will also evaluate the impact of Aczone ® gel on hyperpigmentation and PIH of the face.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: September 20, 2018 | Last Updated: July 04, 2022
Study Completion Date: May 06, 2021
Learn More
Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel
This is a multi center open label study intended to provide photo documentation and time to response data for BPX-01 1 and 2% minocycline topical gel for the treatment of moderate to severe non-nodular inflammatory acne vulgarism.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: October 25, 2016 | Last Updated: July 03, 2022
Study Completion Date: June 01, 2018
Learn More
The Effect of Pretreatment for Propionibacterium Acnes on Surgical Site Burden in Shoulder Arthroplasty
Cutibacterium acnes - formally known as Propionibacter acnes (P. acnes) is the most common pathogen associated with prosthetic joint infection of the shoulder. Despite current skin preparation techniques, P. acnes is encountered at the skin surface and at the natural reservoir in the sebaceous glands during the surgical exposure; current levels of exposure are implicated in overall prosthetic infection risk. Therefore, this study endeavors to decrease P. acnes burden at the surgical incision using preoperative blue light phototherapy and benzyl peroxide washes targeting both the skin surface and sebaceous glands.
Condition: Shoulder Arthroplasty |
Minimum Age: 18 Years
Status: Recruiting |
Phase: Not Applicable
First Posted: July 22, 2019 | Last Updated: June 27, 2022
Study Completion Date: December 31, 2022
Learn More
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to placebo. The study has two periods to explore preliminary dose effects.
Condition: Hidradenitis Suppurativa (Acne Inversa) |
Minimum Age: Years
Status: Completed |
Phase: Phase 2
First Posted: March 18, 2015 | Last Updated: June 17, 2022
Study Completion Date: November 23, 2016
Learn More
Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
The study was designed primarily to assess preliminary efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne and to determine if CJM112 has an adequate clinical profile for further clinical development. In addition, sustainability of response and dose relationship were to be explored.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: December 13, 2016 | Last Updated: June 17, 2022
Study Completion Date: August 01, 2018
Learn More
Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029
A randomized, double-blind, Placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopecia(AGA) or acne
Condition: Acne Vulgaris, Androgenetic Alopecia |
Minimum Age: 18 Years
Status: Recruiting |
Phase: Phase 1
First Posted: March 15, 2022 | Last Updated: June 16, 2022
Study Completion Date: February 10, 2023
Learn More
Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions
Subjects are to be enrolled in this clinical study if they are 18 - 55 years old. Up to 120 subjects will be enrolled at multiple study centers. Subjects may receive up to 5 treatments for a wide array of dermatologic conditions in which electrocoagulation and hemostasis is a viable mechanism for means of improvement.
Condition: Acne, Acne Scars, Crepey Skin, Enlarged Pores, Fine Lines, Loose Skin, Stretch Marks, Wrinkle |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: October 15, 2021 | Last Updated: May 18, 2022
Study Completion Date: June 21, 2021
Learn More
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
The purpose of this study was to demonstrate that daily use of topical trifarotene (CD5789) 50 microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and effective for the treatment of severe AV.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: June 25, 2020 | Last Updated: April 20, 2022
Study Completion Date: April 26, 2021
Learn More
Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris
The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: June 19, 2018 | Last Updated: April 14, 2022
Study Completion Date: September 05, 2019
Learn More
Blue Light Therapy of C. Acnes
This proposal aims to investigate a novel light-based treatment to reduce morbidity in shoulder surgical patients. This has potential to improve outcomes and reduce health care utilization associated with infectious complications of shoulder arthroplasty. Participants will be healthy male volunteers at least 18 years of age. They will be on study for approximately 2 days.
Condition: Acne |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: March 05, 2020 | Last Updated: April 13, 2022
Study Completion Date: January 22, 2021
Learn More
Weekly Isotretinoin Therapy Study
In current Dermatology practice, options for moderate acne vulgaris remain limited. The mainstay of treatment for moderate acne remains long courses of oral antibiotics despite emerging antibiotic resistance. The efficacy of daily to twice daily dosed isotretinoin, an oral vitamin A derivative, for treatment of severe acne has been well established. The purpose of this study is to determine if once weekly dosed isotretinoin is effective for the treatment of patients with moderate acne. Additionally, the study aims to evaluate patient satisfaction and identify any adverse effects on this alternative dosing regimen.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 1/Phase 2
First Posted: October 14, 2020 | Last Updated: April 11, 2022
Study Completion Date: December 21, 2021
Learn More
Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
This study examines the efficacy of a non-thermal, atmospheric plasma device in the treatment of skin disorders
Condition: Acne/Rosacea, Actinic Keratosis, Bowen's Disease, Molluscum Contagiosum, Tinea, Verruca Plana, Warts |
Minimum Age: 4 Years
Status: Recruiting |
Phase: Not Applicable
First Posted: April 26, 2016 | Last Updated: April 10, 2022
Study Completion Date: January 31, 2025
Learn More
A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions
The purpose of this phase 1, multicenter study is to evaluate the safety, tolerability and preliminary efficacy of LUT014 in adult metastatic colorectal cancer patients with EGFR Inhibitor induced acneiform lesions
Condition: EGFR Inhibitor Induced Acneiform Lesions |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: March 11, 2019 | Last Updated: April 05, 2022
Study Completion Date: November 18, 2020
Learn More
A Proof of Concept Study to Evaluate the Efficacy and Tolerability of Microneedling With SkinPen in Female and Male Subjects With Facial Acne Vulgaris, Ages 18 Through 45
This single-center, proof of concept trial is being conducted over the course of 42 days followed by a 2-month post-last treatment visit in order to assess the efficacy and tolerability of the Sponsor's SkinPen device in treating Acne Vulgaris on the face.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: September 22, 2021 | Last Updated: March 24, 2022
Study Completion Date: March 18, 2022
Learn More
A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris
Acne vulgaris is a common disease of both males and females, usually manifesting initially during adolescence. The use of retinoic acid analogues such as adapalene, tazarotene and isotretinoin are also commonly prescribed to treat inflammation; dysregulated sebum production and comedonal acne. This study seeks to evaluate the efficacy and safety of concomitant use of both AMZEEQ® and oral isotretinoin compared to oral isotretinoin only use and to explore sequence dosing of both products as part of a long-term management protocol for acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Active, not recruiting |
Phase: Phase 4
First Posted: June 16, 2021 | Last Updated: March 22, 2022
Study Completion Date: November 30, 2023
Learn More
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: December 30, 2019 | Last Updated: March 15, 2022
Study Completion Date: March 18, 2021
Learn More
Safety and Efficacy of 1550nm Fractional Laser Treatment for Acne Scars in Fitzpatrick Type IV-VI Skin
Fractionated laser resurfacing is commonly used as a treatment for acne scarring in fair skinned individuals. This study aims to test the efficacy and safety in darker skin types. Patients are randomized to either the 10mJ 40mJ dosages and receive a total of five treatments at 17% one month apart. Improvement is judged by a dermatologist as 0-25%, 25-50%, 50-75% or 75-100%. Side effects such as pigmentary abnormalities and pain are also evaluated.
Condition: Acne Scarring |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: March 17, 2008 | Last Updated: March 10, 2022
Study Completion Date: September 30, 2008
Learn More
A Botanical Skin Care Regimen on Mild to Moderate Acne and the Microbiome
The purpose of this study is to analyze changes in acne and changes in the gut and skin microbiome with the use of a multi-step botanical skin care regimen in those with mild to moderate acne.
Condition: Acne Vulgaris |
Minimum Age: 15 Years
Status: Not yet recruiting |
Phase: Not Applicable
First Posted: February 25, 2022 | Last Updated: March 08, 2022
Study Completion Date: March 01, 2023
Learn More
Almond Supplementation on Mild to Moderate Acne
This study will assess the effect of almond supplementation on acne and on gut health.
Condition: Acne Vulgaris |
Minimum Age: 15 Years
Status: Recruiting |
Phase: Not Applicable
First Posted: February 12, 2022 | Last Updated: February 25, 2022
Study Completion Date: December 01, 2024
Learn More
BPO vs Hibiclens Soap for Surgical Preparation
This is a randomized trial of benzoyl peroxide soap versus Hibiclens soap for surgical preparation. The objective is to determine whether benzoyl peroxide soap, commonly available in drug stores for over-the-counter acne treatment, is as or more effective than the standard surgical preoperative soap, Hibiclens soap (chlorhexidine gluconate), in reducing loads of Propionibacteria (Propi) on or under the skin of patients prior to shoulder arthroplasty (joint replacement).
Condition: Propionibacterium Acnes |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: July 01, 2019 | Last Updated: February 16, 2022
Study Completion Date: April 16, 2021
Learn More
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: December 30, 2019 | Last Updated: January 18, 2022
Study Completion Date: January 18, 2021
Learn More
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: May 24, 2016 | Last Updated: January 13, 2022
Study Completion Date: October 13, 2017
Learn More
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: May 24, 2016 | Last Updated: January 13, 2022
Study Completion Date: October 13, 2017
Learn More
A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: August 30, 2017 | Last Updated: January 13, 2022
Study Completion Date: September 04, 2018
Learn More
A Study of S6G5T-3 in the Treatment of Acne Vulgaris
To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: November 30, 2018 | Last Updated: December 14, 2021
Study Completion Date: December 31, 2019
Learn More
A Study of S6G5T3 in the Treatment of Acne Vulgaris
To assess the efficacy of S6G5T-3 compared to its vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: November 30, 2018 | Last Updated: December 14, 2021
Study Completion Date: October 23, 2019
Learn More
Collagen Injections for the Treatment of Acne Scars and Wrinkles
The purpose of this study is to find out if autologous (your own) fibroblast injections are effective for the treatment of acne scars and wrinkles.
Condition: Acne Scars, Wrinkles |
Minimum Age: 18 Years
Status: Terminated |
Phase: Phase 1
First Posted: September 27, 2012 | Last Updated: December 02, 2021
Study Completion Date: June 30, 2013
Learn More
Treatment of Acne Scarring With a Novel Procedure Combination
The primary objective of this study is to look at the efficacy of subdermal manipulation and filler injection in the improvement of acne scar appearance.
Condition: Acne Scarring |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: July 31, 2007 | Last Updated: November 30, 2021
Study Completion Date: July 31, 2009
Learn More
A Pilot Study Testing the Efficacy of a Needling Device for the Treatment of Acne Scars
The primary objective of this study is to determine the efficacy of a needling device for treatment of acne scars.
Condition: Acne Scars |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: September 09, 2009 | Last Updated: November 30, 2021
Study Completion Date: July 31, 2010
Learn More
Sleep, Circadian Rhythm & Skin Health
The purpose of this study is to explore the mechanisms behind how sleep quality may affect skin aging, skin integrity and skin disease.
Condition: Acne, Eczema, Healthy, Psoriasis |
Minimum Age: 18 Years
Status: Completed |
Phase:
First Posted: March 18, 2015 | Last Updated: November 30, 2021
Study Completion Date: August 31, 2020
Learn More
Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris
Participant Reported Outcomes with use of Trifarotene 50 μg/g Cream in participants with Moderate Facial and Truncal Acne Vulgaris
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: April 12, 2019 | Last Updated: November 16, 2021
Study Completion Date: December 23, 2019
Learn More
Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris
The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment acne vulgaris
Condition: Acne |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: July 31, 2015 | Last Updated: November 05, 2021
Study Completion Date: June 30, 2016
Learn More
Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face
To compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of Acne Vulgaris
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: January 03, 2018 | Last Updated: November 05, 2021
Study Completion Date: January 05, 2019
Learn More
Timolol for the Treatment of Acne and Rosacea
This research is being done to determine the safety and tolerability of timolol in the treatment of acne and rosacea. The investigators will also look for specific biomolecular changes in acne or rosacea skin when it is exposed to timolol.
Timolol is approved by the Food and Drug Administration (FDA) for the treatment of glaucoma. In dermatology, it has been used as a treatment to decrease the size of vascular (blood vessel) malformations in infant skin. Timolol is not approved for use in acne or rosacea and its use in this study is investigational.
Many people with rosacea have telangiectasias which are small, red dilated blood vessels on the skin. They also suffer from flushing and acne-like lesions. Better treatments than those currently available are desired.
Acne vulgaris, or acne, is another chronic inflammatory and very common skin disease that affects about 8 out of 10 young adults and adolescents. Signs of acne include papules and blackheads that are often called primary lesions because they represent an active form of the disease. There are also secondary lesions that can form later; they are known as acne scars
Condition: Acne Vulgaris, Rosacea |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: May 09, 2016 | Last Updated: November 04, 2021
Study Completion Date: March 31, 2021
Learn More
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 2
First Posted: May 26, 2017 | Last Updated: October 13, 2021
Study Completion Date: April 23, 2019
Learn More
A Pilot Study to Explore the Role of Gut Flora in Acne
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
Condition: Acne, Acne Conglobata, Acne Cystic, Acne Detergicans, Acne Follicular, Acne Fulminans, Acne Indurata, Acne Inversa, Acne Iodide, Acne Keloid, Acne Keloidalis, Acne Papular, Acne Pomade, Acne Rosacea, Acne Tropica, Acne Tropicalis, Acne Urticata, Acne Varioliformis, Acne Vulgaris |
Minimum Age: Years
Status: Recruiting |
Phase:
First Posted: December 27, 2019 | Last Updated: September 02, 2021
Study Completion Date: July 31, 2023
Learn More
Dose Range Study of CD5789 in Acne Vulgaris
To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: June 08, 2012 | Last Updated: August 23, 2021
Study Completion Date: June 12, 2014
Learn More
Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea
The study evaluated the safety, tolerability, and efficacy of ACCU-D1 when applied twice daily for 12 weeks in adult participants with moderate to severe acne rosacea. Two-third of the participants received ACCU-D1 while one-third of the participants received vehicle control.
Condition: Acne Rosacea |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: February 22, 2017 | Last Updated: August 17, 2021
Study Completion Date: June 18, 2018
Learn More
Sarecycline Truncal Acne Safety and Efficacy Response
The purpose of this study is to determine the efficacy and safety of oral sarecycline 1.5 mg/kg/day in truncal acne. Patients with moderate to severe acne vulgaris will be observed over a period of 12 weeks. Lesion counts, investigator's global assessments, photography, and safety measures will be assessed for the trunk and face.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Active, not recruiting |
Phase:
First Posted: August 11, 2021 | Last Updated: August 17, 2021
Study Completion Date: October 31, 2021
Learn More
Efficacy of Oral Minocycline (Solodyn) and Oral Minocycline (Solodyn) Plus Azelaic Acid (Finacea) for Acne Rosacea
Rosacea is one of the most commonly occurring dermatoses treated by dermatologist today. Rosacea is an inflammatory condition of the skin presenting as flushing and or blushing along with redness, swelling, telangiectasia, and acne lesions. Minocycline has shown beneficial in the treatment of inflammatory acne lesions in patients with rosacea. This study is to evaluate the efficacy and tolerability of minocycline (Solodyn) alone versus minocycline (Solodyn) in combination with azelaic acid 15%(Finacea) in the treatment of rosacea.
Condition: Rosacea |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: November 22, 2013 | Last Updated: August 13, 2021
Study Completion Date: September 30, 2011
Learn More
De Novo Lipogenesis of Sebaceous Glands in Acne
There are two purposes of this study:
First, the investigators want to see what the differences are in de novo sebaceous lipid production of people with and without acne.
Secondly, the investigators want to know what happens to sebaceous gland de novo lipid production before and after treatment with topical tretinoin and oral isotretinoin.
Condition: Acne Vulgaris |
Minimum Age: 15 Years
Status: Completed |
Phase: Early Phase 1
First Posted: December 01, 2015 | Last Updated: August 04, 2021
Study Completion Date: October 12, 2017
Learn More
Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers
The purpose of this study is assess the safety and tolerability of lemuteporfin topical solution (LTS) with exposure to red light (PDT), when applied to the backs of healthy volunteers.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: April 10, 2013 | Last Updated: July 16, 2021
Study Completion Date: June 30, 2013
Learn More
A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris
The objectives of this study are to assess the safety and efficacy DRM01 Topical Gel compared to vehicle in patients with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: April 27, 2015 | Last Updated: July 16, 2021
Study Completion Date: April 30, 2016
Learn More
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
The objectives of this study are to assess the safety and efficacy of Olumacostat Glasaretil Gel compared to vehicle in patients with acne vulgaris
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: January 19, 2017 | Last Updated: July 16, 2021
Study Completion Date: November 28, 2017
Learn More
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
The objectives of this study are to assess the safety and efficacy of Olumacostat Glasaretil Gel compared to vehicle in patients with acne vulgaris
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: March 03, 2017 | Last Updated: July 16, 2021
Study Completion Date: December 21, 2017
Learn More
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
The objective of this study is to assess the long-term safety of Olumacostat Glasaretil gel, 5.0% in patients with acne vulgaris
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: April 17, 2017 | Last Updated: July 16, 2021
Study Completion Date: April 27, 2018
Learn More
SkinPen Efficacy on Acne Scars on the Face and/or Back
This single-center, clinical trial will take place over a 90 day course followed by 1-month and 6-month post treatment visits to assess the efficacy and tolerability of the SkinPen device when used on both men and women on the face and/or back.
Condition: Atrophic Acne Scar |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: December 21, 2015 | Last Updated: June 30, 2021
Study Completion Date: July 25, 2017
Learn More
Comparison of 1,550 and 755 Laser in a Split-face Trial
Clinical Trial comparing the 1,550-nanometer fractionated photothermolysis system laser to the 755 nanometer picosecond laser using a split-face (Right-Left) comparison. Patients will receive laser treatments at week 0, week 4, and week 8. Photographs will be taken prior to laser treatment at each visit, and at the week 24 follow-up visit. Photographs will be reviewed by blinded assessors to rate each side of the face and change from baseline photos.
Condition: Acne Scars - Mixed Atrophic and Hypertrophic |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: December 06, 2017 | Last Updated: June 08, 2021
Study Completion Date: October 30, 2019
Learn More
Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles
The objective of this clinical study is to evaluate the efficacy of fractional RF for the treatment and reduction of acne scarring or facial wrinkles.
Condition: Acne Scars - Mixed Atrophic and Hypertrophic, Wrinkle |
Minimum Age: 22 Years
Status: Completed |
Phase: Not Applicable
First Posted: August 13, 2019 | Last Updated: June 08, 2021
Study Completion Date: March 03, 2020
Learn More
Irrisept C.Acnes Study
A Prospective, Randomized, Controlled Trial Comparing An Irrisept Antiseptic Irrigation With 0.05% Chlorhexidine Gluconate versus Standard of Care Prophylaxis Chlorohexidine Wipes
Condition: Rate of Positive Culture Growth for C.Acnes From Specimens Obtained From the Shoulders of Patients Undergoing Primary Shoulder Arthroplasty |
Minimum Age: 18 Years
Status: Recruiting |
Phase: Phase 4
First Posted: May 02, 2019 | Last Updated: May 20, 2021
Study Completion Date: October 01, 2023
Learn More
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
This study further evaluates the efficacy of bermekimab in treating moderate to severe hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of bermekimab, 1/3 will receive alternating every other week injections of bermekimab or placebo, and 1/3 will receive weekly injections of placebo.
Condition: Acne Inversa, Hidradenitis Suppurativa, Suppurative Hidradenitis |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: July 09, 2019 | Last Updated: May 17, 2021
Study Completion Date: November 17, 2020
Learn More
Study To Investigate If Embody's Retinol Gummies Improve The Early Signs Of Skin Aging And Overall Skin Health
The Embody retinol study is a single-arm clinical trial on skin aging prevention and adult acne. The purpose of this study is to determine the effect of a retinol gummy in adults aged 18-45 on skin aging and overall skin health.
Condition: Acne, Adult |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: May 06, 2021 | Last Updated: May 11, 2021
Study Completion Date: April 15, 2021
Learn More
A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris
To demonstrate the therapeutic equivalence and safety of Tretinoin Gel Microsphere, 0.1% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% (Valeant) in the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Early Phase 1
First Posted: May 07, 2021 | Last Updated: May 07, 2021
Study Completion Date: April 16, 2021
Learn More
ABSORICA in Patients With Severe Recalcitrant Nodular Acne
This is an uncontrolled, open-label study being conducted in approximately 200 healthy males, non-pregnant, non-nursing females, age 12 to 45 years, with severe recalcitrant nodular acne.
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day will be administered for 4 weeks followed by 1.0 mg/kg/day for 16 weeks. Female subjects consenting to use two forms of birth control or abstinence are included.
Condition: Acne |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: May 16, 2015 | Last Updated: April 26, 2021
Study Completion Date: April 30, 2018
Learn More
The Functional and Emotional Benefits of Replenix Power of Three With Resveratrol
A Randomized, Investigator Blinded, Single Site, Three Arm Clinical Study to Assess the Functional and Emotional Benefits of Replenix Power of Three Cream with Resveratrol , Replenix Power of Three Cream with Resveratrol with Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, utilized to treat subjects with Facial Acne Vulgaris
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Terminated |
Phase: Phase 4
First Posted: May 23, 2018 | Last Updated: April 20, 2021
Study Completion Date: March 02, 2021
Learn More
Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris
The objective of the study is to evaluate the safety, tolerability, and therapeutic equivalence of GDC 268 to Clindamycin Phosphate Topical Lotion, 1% and to compare the efficacy of these two products to the GDC vehicle lotion (i.e., placebo) in the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: October 22, 2018 | Last Updated: April 09, 2021
Study Completion Date: April 16, 2020
Learn More
A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)
This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: May 24, 2017 | Last Updated: March 30, 2021
Study Completion Date: June 07, 2018
Learn More
A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)
This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: May 24, 2017 | Last Updated: March 30, 2021
Study Completion Date: July 24, 2018
Learn More
Clinical Evaluation of Fractional Radiofrequency for the Treatment Acne Scarring
Prospective, single centre, evaluator-blind study of the safety and performance of fractional radiofrequency (RF) for the treatment and reduction of acne scarring. The study will evaluate the progress of 15 subjects requesting treatment of acne scarring. The study will involve three treatments on both sides of the face with 3-5 week intervals between each treatment. Subjects will be followed at 6 and 12 weeks after their last treatment. Analysis will be performed on all subjects who receive at least one treatment.
Condition: Acne Scars |
Minimum Age: 22 Years
Status: Completed |
Phase: Not Applicable
First Posted: January 28, 2019 | Last Updated: March 30, 2021
Study Completion Date: October 03, 2019
Learn More
A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris
The bioequivalence and safety of Tretinoin Cream 0.025% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A® (Tretinoin) Cream 0.025% in the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Early Phase 1
First Posted: January 21, 2021 | Last Updated: March 29, 2021
Study Completion Date: November 21, 2020
Learn More
A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
To demonstrate therapeutic equivalence and safety of adapalene gel 0.1% (Taro Pharmaceuticals U.S.A., Inc.) and Differin® Gel (Adapalene Gel 0.1%, Galderma) in the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Early Phase 1
First Posted: March 12, 2021 | Last Updated: March 26, 2021
Study Completion Date: January 08, 2021
Learn More
A Study Comparing Two Topicals in the Treatment of Acne Vulgaris
A Randomized, Evaluator-Blinded, Bilateral Comparison Study to Evaluate the Safety and Efficacy of Two Topicals in the Treatment of Subjects With Acne Vulgaris (Study FX2018-23).
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 1
First Posted: November 10, 2018 | Last Updated: March 11, 2021
Study Completion Date: February 11, 2019
Learn More
Clinical Evaluation of Fractional Radiofrequency for the Treatment of Acne Scarring
Prospective, single centre, evaluator-blind study of the safety and performance of fractional radiofrequency (RF) for the treatment and reduction of acne scarring. The study will evaluate 50 treatment sites in subjects requesting treatment of their acne scarring. The study will involve three treatments on both sides of the face with 3-5 week intervals between each treatment. Subjects will be followed at 6 and 12 weeks after their last treatment. Analysis will be performed on all subjects who receive at least one treatment.
Condition: Acne Scars |
Minimum Age: 22 Years
Status: Completed |
Phase: Not Applicable
First Posted: December 03, 2018 | Last Updated: February 26, 2021
Study Completion Date: December 22, 2019
Learn More
Pain Outcomes Following Intralesional Corticosteroid Injections
Corticosteroid therapy, including intralesional and topical applications, has many indications within the fields of Dermatology, Plastic Surgery, and Orthopedics. However, these injections can be quite painful, which leads many patients to discontinue treatment.
Often, the injection involves a mixture of local anesthetic and corticosteroids despite a lack of evidence that the use of lidocaine improves pain. Due to the acidic pH, the lidocaine component of the injection can actually cause a significant burning sensation during the procedure. Lidocaine does not have anti-inflammatory properties and does not treat the underlying pathology. By including another medication, lidocaine also adds cost and risk to the procedure.
The purpose of this study is to see if removing lidocaine from intralesional injections decreases the pain of injection.
Condition: Acne, Alopecia Areata, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Granuloma Annulare, Hypertrophic Scar, Keloid, Keratoacanthoma, Lichen Plano-Pilaris, Lichen Planus, Lichen Simplex Chronicus, Morphea, Nummular Eczema, Plaque Psoriasis, Prurigo Nodularis |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: August 09, 2018 | Last Updated: February 18, 2021
Study Completion Date: September 01, 2019
Learn More
A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a subject should remain the same during the study.
The primary objective is to demonstrate the superiority in efficacy and assess safety of Adapalene/Benzoyl Peroxide Topical Gel (Adapalene/Benzoyl Peroxide Gel) versus Adapalene Topical Gel, 0.1% (Adapalene Monad); Benzoyl Peroxide Topical Gel, 2.5% (Benzoyl Peroxide Monad) and Topical Gel Vehicle (Gel Vehicle) in the treatment of acne vulgaris for up to 12 weeks.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: January 11, 2007 | Last Updated: February 16, 2021
Study Completion Date: December 31, 2007
Learn More
Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a subject should remain the same during the study.
The primary objective is to demonstrate the superiority in efficacy and assess safety of adapalene/benzoyl peroxide topical gel (adapalene/benzoyl peroxide gel) versus adapalene topical gel, 0.1% (adapalene monad); benzoyl peroxide topical gel, 2.5% (benzoyl peroxide monad) and topical gel vehicle (gel vehicle) in the treatment of acne vulgaris for up to 12 weeks.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: January 11, 2007 | Last Updated: February 16, 2021
Study Completion Date: July 31, 2007
Learn More
Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris
The purpose of this study is to demonstrate the non-inferior efficacy of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel when compared to Clindamycin 1% / Benzoyl Peroxide 5% Gel in Subjects with acne vulgaris after a 12-week treatment period.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: February 27, 2007 | Last Updated: February 16, 2021
Study Completion Date: October 31, 2007
Learn More
A Long-term Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
This is a multi-centre, open-label, non-comparative study to evaluate the long-term safety and efficacy profile of Adapalene/Benzoyl Peroxide Gel.
Subjects are evaluated at Baseline, Weeks 1 and 2, and Months 1, 2, 4, 6, 8, 10, and 12.
Safety is evaluated by spontaneous reports of Adverse Events (AEs), the Local Tolerability Assessment (Erythema, Scaling, Dryness, and Stinging/Burning), routine laboratory testing (haematology, blood chemistry, and urinalysis), and monitoring of suspected sensitizations. Efficacy is evaluated by analysis of Percent Change from Baseline in Inflammatory, Noninflammatory, and Total Lesion Counts, and by the Subject's Assessment of Acne.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: March 08, 2007 | Last Updated: February 16, 2021
Study Completion Date: May 31, 2004
Learn More
Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%
The purpose of this study is to determine whether Adapalene, 0.1% is safe and effective in the treatment of Acne Vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: January 11, 2008 | Last Updated: February 16, 2021
Study Completion Date: November 30, 2008
Learn More
Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%
The purpose of this study is to determine whether Adapalene, 0.1% is safe and effective in the treatment of Acne Vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: January 11, 2008 | Last Updated: February 16, 2021
Study Completion Date: December 31, 2008
Learn More
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
Phase 4 commitment pharmacokinetic study to determine systemic exposure to adapalene.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: April 15, 2008 | Last Updated: February 16, 2021
Study Completion Date: November 30, 2008
Learn More
Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance
The purpose of this study is to demonstrate the efficacy of Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel compared to its Vehicle Gel as an acne maintenance treatment in Subjects previously treated with Adapalene-BPO Gel or Adapalene-BPO Vehicle Gel both associated with Doxycycline Hyclate 100 mg. The safety of the two investigational treatments will also be assessed.
Condition: Acne |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: May 28, 2008 | Last Updated: February 16, 2021
Study Completion Date: July 31, 2009
Learn More
Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
The purpose of this study is to demonstrate the efficacy of Adapalene 0.1% / Benzoyl Peroxide (quoted as BPO) 2.5% Gel associated with Doxycycline Hyclate 100 mg Tablets compared to Adapalene 0.1% /Benzoyl Peroxide 2.5% Vehicle Gel associated with Doxycycline Hyclate 100 mg Tablets, in the treatment of severe acne vulgaris. The safety of the two treatment regimens will also be evaluated.
Condition: Severe Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: May 28, 2008 | Last Updated: February 16, 2021
Study Completion Date: February 28, 2009
Learn More
Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne
The purpose of the study is to evaluate the efficacy of CD07223 1.5% Gel and 0.5% gel in reducing inflammatory, non-inflammatory, and total acne lesion counts after 6 weeks of twice daily applications. The study will also evaluate the safety of the study products using tolerance and adverse event data.
Condition: Acne |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: April 19, 2010 | Last Updated: February 16, 2021
Study Completion Date: September 30, 2010
Learn More
Epiduo Pediatric Acne Study
The purpose of this study is to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% administered once daily for up to 12 weeks in subjects 9 to 11 years of age with acne vulgaris.
Condition: Acne |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 4
First Posted: June 04, 2010 | Last Updated: February 16, 2021
Study Completion Date: August 31, 2011
Learn More
Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars
The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the treatment of atrophic acne scars.
Condition: Acne Scars |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: September 30, 2010 | Last Updated: February 16, 2021
Study Completion Date: September 30, 2012
Learn More
Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris
The primary objectives of the study is to show CD2475/101 40mg tablets taken once a day for 16 weeks is superior to the placebo in Change from baseline to Week 16(Last Observation Carry Forward, Intent To Treat) in inflammatory lesion counts.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: March 21, 2011 | Last Updated: February 16, 2021
Study Completion Date: January 03, 2012
Learn More
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
This is a multicenter open-label, prospective study in subjects with dark skin from one of the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American and with moderate to severe acne vulgaris on the face.
All eligible subjects will receive Adapalene 0.3% - BPO 2.5% gel (Epiduo Forte/TactuPump Forte) once daily on whole face.
The purpose of this trial is to evaluate subject reported outcomes with the combination of Adapalene 0.3% - BPO 2.5%, Epiduo Forte / TactuPump Forte gel, after 16 weeks of treatment of moderate to severe acne in dark skin phototypes (IV to VI).
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: October 11, 2016 | Last Updated: February 16, 2021
Study Completion Date: January 10, 2018
Learn More
Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris
This is a 91-day phase II, open label trial of the true human monoclonal antibody RA-18C3 in subjects with moderate to severe acne vulgaris. Ten (10) subjects will receive RA-18C3 via subcutaneous injection. Subjects will receive injections at Days 0, 21, and 42 for a total of 3 injections. Study drug will be administered under close observation in a facility equipped to handle medical emergencies. Subjects will not be discharged from the facility until at least 1 hour following the injection or 1 hour after their vital signs have stabilized. Safety will be assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, and the recording of adverse clinical events.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: November 15, 2011 | Last Updated: February 12, 2021
Study Completion Date: December 31, 2012
Learn More
Nourishing Hair, Skin & Nails Supplement Study (Derm Aid)
A 90 day eight arm virtual interventional study looking at the impact of various supplement formulations for improves in hair, skin & nail health via self report, and dermatology assessment via remote dermatologist assessment.
Condition: Cosmetic Acne, Hair Loss, Nails; Soft, Skin Aging, Skin Laxity |
Minimum Age: 26 Years
Status: Completed |
Phase: Phase 3
First Posted: January 25, 2020 | Last Updated: February 09, 2021
Study Completion Date: February 09, 2021
Learn More
Joovvin' for Your Skin Health Study
Sixty day single arm trial examining self-report and remote dermatology assessment of cosmetic skin health after daily 10-20 minute sessions with an infrared light therapy device (the Joovv Mini)
Condition: Acne, Dermatological Non-Disease, Eczema, Skin Condition, Skin Diseases, Skin Inflammation |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: July 11, 2020 | Last Updated: February 09, 2021
Study Completion Date: February 01, 2021
Learn More
A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris
Enrollment of subjects with mild to moderate facial acne. Efficacy was assessed by using an Investigator's Global Assessment scale (IGA 5 point scale) and by counting the number of inflammatory and non-inflammatory lesions on the face at Baseline and Weeks 4, 8, and 12.
Safety assessments included the investigator's assessment of local cutaneous tolerance of the treated skin (dryness, non-lesional erythema, peeling, stinging, burning, and itching, vital signs, and adverse events (AEs).
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: September 19, 2017 | Last Updated: February 04, 2021
Study Completion Date: April 19, 2018
Learn More
A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
Enrollment of subjects with mild to moderate facial acne vulgaris.
Co-Primary efficacy endpoints included:
Absolute change from Baseline to Week 12 in the inflammatory lesion counts on the face
Absolute change from Baseline to Week 12 in the non-inflammatory lesion counts on the face
Proportion of subjects with a clinical response of "success" at Week 12 for lesions on the face. Success based on IGA is defined as an IGA score of 0 (Clear) or 1 (Almost clear) at Week 12 with at least a 2-grade reduction from Baseline.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: September 21, 2017 | Last Updated: February 04, 2021
Study Completion Date: May 14, 2018
Learn More
A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris
This was a multicenter, randomized, multiple-dose, laboratory-blinded, open-label, 2-arm, parallel-arm study in subjects with moderate acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 2
First Posted: June 29, 2018 | Last Updated: February 04, 2021
Study Completion Date: April 30, 2018
Learn More
A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.
A study comparing FCD105 to 3% minocycline foam, 0.3% adapalene foam and vehicle foam in patients ≥ 12 years old for the treatment of moderate-to-severe acne.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: September 24, 2019 | Last Updated: February 02, 2021
Study Completion Date: March 03, 2020
Learn More
Skin Hydration in Persons With Acne After Dietary Supplementation With Botanical Antioxidants
Antioxidants have been studied for their abilities to combat reactive oxygen species in a multitude of conditions. This study aims to assess whether the botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB), taken orally daily for 8 weeks, can assist with Acne vulgaris as well as skin hydration and quality of life for those with acne.
Condition: Acne, Acne Vulgaris |
Minimum Age: 18 Years
Status: Withdrawn |
Phase: Not Applicable
First Posted: August 26, 2020 | Last Updated: January 25, 2021
Study Completion Date: January 24, 2023
Learn More
Clinical Study to Evaluate the Safety and Effectiveness of the Treatment With Tixel C on Acne Scars
The purpose of this research is to evaluate the safety and effectiveness of the Tixel C device for the treatment of acne scars, for improvement in the appearance of surface texture.
Condition: Scars |
Minimum Age: 18 Years
Status: Withdrawn |
Phase: Not Applicable
First Posted: February 06, 2020 | Last Updated: January 10, 2021
Study Completion Date: January 10, 2021
Learn More
Acne Vulgaris Related Microbiology and Serology
This will be an investigation to determine the quality of the serological immune responses against Propionibacterium acnes (P. acnes) in acne patients compared to healthy individuals. In particular, the investigators will measure serum antibody titers against P. acnes surface antigens, and the efficiency of antibody-mediated phagocytic killing of P. acnes.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase:
First Posted: August 05, 2019 | Last Updated: January 05, 2021
Study Completion Date: September 30, 2019
Learn More
Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars
The purpose of this study is to assess treatment of facial acne scars using the 755nm Alexandrite Laser with lens arrays.
Condition: Acne Scars |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: March 31, 2014 | Last Updated: December 22, 2020
Study Completion Date: May 31, 2015
Learn More
The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars
The purpose of this study to evaluate the SmartLipo Triplex laser system along with the SideLaze800 hand piece in the treatment of Acne Scars.
Condition: Acne Scars |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: April 01, 2014 | Last Updated: December 16, 2020
Study Completion Date: February 28, 2015
Learn More
A Pilot Study on the Use of Seysara for Rosacea
This is a prospective, parallel group, randomized, investigator-blinded pilot study. Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a weight-based dose per label or Centrum Adult Multivitamin to take by mouth daily. The study is comprised of 5 visits: screening, baseline, week 4, week 8, and week 12. Investigators will perform rosacea IGA (Investigator Global Assessment,) inflammatory lesion count, record adverse events and con meds, and ask each subject to complete a DLQI (Dermatology Life Quality Index.)
Condition: Acne Rosacea |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: September 14, 2020 | Last Updated: December 14, 2020
Study Completion Date: October 01, 2020
Learn More
Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris
This study is being conducted to characterize the safety and tolerability of BOS-356 in adult participants with moderate to severe acne vulgaris following 14 days or 28 days of repeated topical application
Condition: Moderate to Severe Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: November 12, 2019 | Last Updated: November 25, 2020
Study Completion Date: November 11, 2020
Learn More
Oral Probiotics on the Microbiome and Lipidome in Acne Vulgaris
The purpose of this study is to determine how probiotics affect sebum production and gut health in those with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 13 Years
Status: Unknown status |
Phase: Not Applicable
First Posted: October 09, 2020 | Last Updated: November 20, 2020
Study Completion Date: March 31, 2021
Learn More
Photodynamic Therapy for Cutibacterium Acnes (C. Acnes) Decolonization of the Shoulder Dermis
This is a prospective, randomized controlled trial to evaluation the ability of 5-aminolevulinic acid HCL topical solution photodynamic therapy to decrease the colonization of Cutibacterium acnes (C. acnes- a bacteria commonly found in the dermis of the skin surrounding the shoulder) in order to decrease postoperative joint infections.
-Aminolevulinic acid (ALA) is a naturally occurring metabolite in the synthesis of pathway of cellular heme production. Adding ALA to bacteria encourages porphyrin production which serve as the immediate precursors to heme production. When these porphyrins are illuminated with blue light at an emission peak of 407-420nm, these metabolites become exothermic and cause internal destruction of the bacterial cells. This therapy does not cause any damage to the mammalian cells, which makes PDT safe for human skin treatment.
Condition: Arthroscopic Rotator Cuff Repair, C. Acnes, Phototherapy, Postoperative Infection, Shoulder Surgery |
Minimum Age: 18 Years
Status: Unknown status |
Phase: Phase 3
First Posted: October 21, 2020 | Last Updated: November 18, 2020
Study Completion Date: August 31, 2021
Learn More
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in subjects with acne vulgaris ages 12 years or older.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: April 11, 2013 | Last Updated: November 16, 2020
Study Completion Date: November 30, 2013
Learn More
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in pediatric patients 9 to less than 12 years of age with acne vulgaris. Adrenal suppression effects and systemic safety are an important safety concern. The current study is designed to investigate these potential concerns under maximal use conditions.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 2
First Posted: March 22, 2016 | Last Updated: November 03, 2020
Study Completion Date: March 21, 2018
Learn More
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: November 17, 2015 | Last Updated: October 29, 2020
Study Completion Date: April 11, 2018
Learn More
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: November 17, 2015 | Last Updated: October 29, 2020
Study Completion Date: February 21, 2018
Learn More
An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris
The primary objective of this study is to determine the long-term safety of CB-03-01 cream, 1% applied twice daily for an additional nine months in study participants with acne vulgaris that participated in the Phase 3 pivotal studies for a total treatment of up to 12 months.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: February 10, 2016 | Last Updated: October 26, 2020
Study Completion Date: August 31, 2018
Learn More
Sebacia Postmarket Study of Real-World Use
Postmarket study of Sebacia Microparticles treatment during adoption into clinical use for patients with mild to moderate inflammatory acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Unknown status |
Phase: Not Applicable
First Posted: January 24, 2019 | Last Updated: October 24, 2020
Study Completion Date: June 30, 2021
Learn More
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent skin disorder. The purpose of this study is to compare the safety and efficacy of multiple concentrations of CB-03-01 to vehicle in the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: June 27, 2012 | Last Updated: October 22, 2020
Study Completion Date: February 28, 2014
Learn More
Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.
This is an exploratory Phase 2 trial of BMX-010 in patients with Acne Vulgaris which will be conducted in two parts. Up to 210 subjects with Acne Vulgaris will be enrolled.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Terminated |
Phase: Phase 2
First Posted: November 15, 2018 | Last Updated: October 19, 2020
Study Completion Date: August 31, 2020
Learn More
Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris
The purpose of the study is to evaluate the efficacy of facial acne vulgaris treatment using the Venus Versa Diamondpolar applicator in combination with the Venus Versa AC dual applicator using two intense pulsed light wavelength bands.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Terminated |
Phase: Not Applicable
First Posted: September 30, 2016 | Last Updated: October 15, 2020
Study Completion Date: October 31, 2018
Learn More
Acne and Mood: Impact of Treatment on Depression, Anxiety, and Sexual Function
This study seeks to examine if there is any relationship between spironolactone use prescribed for acne vulgaris and depression, anxiety, and/or sexual function.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Withdrawn |
Phase:
First Posted: April 16, 2019 | Last Updated: October 07, 2020
Study Completion Date: December 31, 2020
Learn More
To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
This is an Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study.
The main objective is to evaluate bioequivalence of Test formulation (Clindamycin Phosphate 1.2%/Benzoyl peroxide 5% gel) of Cadila Healthcare with Reference formulation (DUAC® Gel of Stiefel Laboratories)in the ratio of 2:2:1 of Test drug, Reference drug and Placebo respectively.
Total study duration will be for a period of 78 days which includes treatment duration of 77 days.
850 subjects will be enrolled (randomized)as per the inclusion and exclusion criteria mentioned in the protocol.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: November 28, 2013 | Last Updated: September 18, 2020
Study Completion Date: September 28, 2016
Learn More
Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris
This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1% gel (Akorn), and the marketed product Clindamycin 1% gel (Greenstone LLC) in the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: April 23, 2018 | Last Updated: September 11, 2020
Study Completion Date: April 22, 2019
Learn More
Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris
Safety and Efficacy of IDP-123 Lotion (0.045% tazarotene) to Tazorac® (tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: October 11, 2016 | Last Updated: September 03, 2020
Study Completion Date: September 30, 2016
Learn More
Fractional Ablative Radiofrequency for the Treatment of Acne Scars and Wrinkles
To assess the safety and efficacy of the Pixel RF (fractional radio frequency) module in the treatment of acne scars and wrinkles.
Condition: Acne Scars, Wrinkles |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: July 13, 2012 | Last Updated: August 20, 2020
Study Completion Date: March 31, 2013
Learn More
Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
The study team plans to enroll a total of 40 subjects with self-reported perimenstrual acne. Eligible women will be over the age of 18 and not on any current therapy. The patients will first arrive for a screening visit, where they will be given questionnaires on acne quality of life (acne QOL) and subjective assessments as well as flare ups (as used in the study by Geller et al). The patients' skin will be assessed for inflammatory and non-inflammatory acne vulgaris. The baseline visit (day 1) will be scheduled for one week prior to the first day of menses (as studies indicate that most women have their acne flare during this time). The study team will perform a zit count (counting papules, pustules, and comedones) and global assessment, and the patient will be instructed to record their menses (which they will do for the duration of the study). The patients will then return in 2 weeks, at day 15, and they will be re-assessed. The patients will be dispensed the investigational product and instructed on its daily use. The patients will continue to return every 14 days to have their skin assessed until their final visit on day 99, one week after their 3rd menses on treatment (4th menses on study). The duration of the study per patient is approximately 4 months, and the study team anticipates an enrollment period of 12 months.
Condition: Actinic Keratosis |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: April 17, 2017 | Last Updated: August 18, 2020
Study Completion Date: July 19, 2018
Learn More
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
A study for Subjects with mild to moderate facial acne vulgaris. During the 12-week treatment period subjects randomized to DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily. Subjects randomized to Tazorac Cream or Vehicle Cream will use the study drug once daily in the evening. Safety assessments will include the investigator's assessment of local cutaneous tolerance/application site reactions on the face, vital signs and adverse events.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 2
First Posted: October 13, 2017 | Last Updated: August 13, 2020
Study Completion Date: May 18, 2018
Learn More
DMT310-001 Topical in the Treatment of Acne Vulgaris
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: May 02, 2018 | Last Updated: July 20, 2020
Study Completion Date: January 28, 2019
Learn More
DMT310-003 Topical in the Treatment of Acne Vulgaris
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: September 25, 2019 | Last Updated: July 20, 2020
Study Completion Date: May 04, 2020
Learn More
A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne
Acne vulgaris is a multifactorial disease caused by overgrowth of Propionibacterium acnes (P. acnes), impaction of hair follicles, excessive sebum production and hormonal dysregulation. Recent literature from the Human Microbiome Project has shown there are unique microbial signatures specific to healthy and acne disease states.
From this data, the investigators hypothesize that by eliminating resident disease-associated bacterial strains and replacing them with health-associated strains, recurrences/fares of acne may be improved, mitigated, and prevented. Instead of current approaches which focus on eliminating all bacteria from the skin, the investigators aim to deliver healthy bacteria to restore the skin to a healthy state via this replacement therapy.
The investigators aim to test this in a Phase Ib single application study evaluating the safety, tolerability, and clinical impact that a single application of NB01, a live strain of P. acnes, has on adult subjects with moderate acne.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: February 13, 2018 | Last Updated: July 10, 2020
Study Completion Date: June 18, 2018
Learn More
A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne
Acne vulgaris is a disease caused my multiple factors including overgrowth of bacteria, clogged pores, excessive sebum production and hormonal changes. Recent literature from the Human Microbiome Project has shown there are bacterial strains specific to healthy and acne disease states (Fitz-Gibbon et al, 2013, Johnson et al, 2016, McDowell et al, 2012, Tomida et al, 2013)
From this data, the investigators hypothesize that by eliminating disease-associated bacterial strains and replacing them with health-associated strains, recurrences or flares of acne may be improved, mitigated, and prevented. Instead of current approaches which focus on eliminating all bacteria from the skin, the investigators aim to deliver healthy bacteria to restore the skin to a healthy state via this replacement therapy.
The investigators aim to test this in a Phase Ib multiple application study evaluating the safety, tolerability, and clinical impact that a multiple applications of NB01 have on adult subjects with moderate acne.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: October 09, 2018 | Last Updated: July 09, 2020
Study Completion Date: September 30, 2019
Learn More
Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel, 0.3%/2.5% (Actavis Laboratories UT, Inc.) to Epiduo® Forte (adapalene and benzoyl peroxide) gel 0.3%/2.5% (Galderma) in the treatment of Acne Vulgaris
Condition: Acne |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: January 05, 2016 | Last Updated: June 09, 2020
Study Completion Date: October 31, 2016
Learn More
A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris
The purpose of this study is to compare the safety and therapeutic equivalence of a generic tazarotene foam 0.1% and the reference listed Fabior™ (tazarotene foam, 0.1%) in the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: October 14, 2014 | Last Updated: May 29, 2020
Study Completion Date: September 30, 2014
Learn More
Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris
Actavis has developed a generic formulation of clindamycin 1.2% and benzoyl peroxide 3.75% gel. This study is designed to evaluate the safety and efficacy of this formulation in subjects with Acne Vulgaris
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: November 25, 2015 | Last Updated: May 14, 2020
Study Completion Date: November 30, 2015
Learn More
The Use of Bellafill for Atrophic Acne Scar Correction in the Full Facial Area
This is an open-label, multicenter, prospective pilot study assessing the efficacy and safety of Bellafill for correction of distensible atrophic acne scars in the full facial area. All enrolled subjects will receive initial treatment with Bellafill, as well as touch-up treatments (if necessary to achieve optimal correction). Subjects will be evaluated at Screening (Month -1), Day 0 (Baseline) Month 1, Month 4, and Month 7.
Condition: Atrophic Acne Scarring |
Minimum Age: 21 Years
Status: Completed |
Phase: Not Applicable
First Posted: December 28, 2015 | Last Updated: April 03, 2020
Study Completion Date: January 27, 2017
Learn More
Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
To evaluate the therapeutic effect of Dapsone and Placebo gel in the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: July 06, 2019 | Last Updated: April 01, 2020
Study Completion Date: February 22, 2020
Learn More
Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne
Comparison of efficacy and safety of Azelaic Acid 15% gel with its vehicle in male and female patients with mild to moderate acne.
Qualified subjects will apply the gel to their face twice a day for a period of 12 weeks. Subjects will be required to return to the doctor's office for up to 5 visits.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: February 21, 2002 | Last Updated: March 30, 2020
Study Completion Date: July 31, 2002
Learn More
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is an under-recognized and debilitating disease. Patients suffer from recurring painful abscesses and scarring in their armpits, under the breasts, groin and other areas of the body. The cause of the disease is still unknown and common treatments are only sometimes effective. Overactivity of the immune system has been associated with HS and molecules that cause inflammation have been found in the skin from people with HS. Current therapies have long-term risks including antibiotic resistance and the investigators aim to find new safe and effective therapies for HS.
Hydroxychloroquine is a medication that has been used safely in other diseases for many years. The investigators believe that hydroxychloroquine has the potential to improve HS through multiple mechanisms. Patients enrolled in this study will be treated with hydroxychloroquine for 6 months. The investigators also aim to look at the blood of patients with HS to look for inflammatory molecules that we could possibly target for the treatment of HS. Blood samples will be taken at baseline and following 6 months of treatment.
Condition: Acne Inversa, Boils, Follicular Occlusion Tetrad, Follicular Occlusion Triad, Hidradenitis, Hidradenitis Suppurativa |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1/Phase 2
First Posted: August 31, 2017 | Last Updated: March 23, 2020
Study Completion Date: June 30, 2019
Learn More
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 1
First Posted: March 23, 2020 | Last Updated: March 23, 2020
Study Completion Date: March 06, 2020
Learn More
MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3
To assess the degree of systemic exposure of S6G5T-3 compared to the Reference Listed Drug (RLD) Retin-A® 0.1% Cream when applied topically once daily for 14 days, under maximal use conditions in adolescents ≥12 years of age and adults with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 1
First Posted: August 01, 2019 | Last Updated: March 17, 2020
Study Completion Date: February 06, 2020
Learn More
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
This study will evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of ACZONE Gel, 7.5% administered topically once-daily for 12 weeks in 9 to 11 year-olds with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 4
First Posted: November 07, 2016 | Last Updated: February 19, 2020
Study Completion Date: March 09, 2018
Learn More
Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris
Acne vulgaris is a multifactorial, highly prevalent dermatologic condition that results in visible lesions that can be quite disfiguring. Consequently, individuals with acne often suffer from a wide range of psychological manifestations. Although there is consensus that combination therapy is most effective in treating acne, researchers are constantly striving to develop new treatment. Microcurrent therapy (MCT) is a non-invasive modality that has successfully been used to promote wound healing and has been routinely used in aesthetics. Use of MCT alone or in combination with current successful treatment such as blue light phototherapy (BLP), may hold promise for acne treatment. The investigators propose to conduct a small randomized control trial to determine the safety and preliminary efficacy of a novel combination therapy to treat acne vulgaris. The investigators will recruit up to 60 males and females and randomly assign them to one of 3 arms: 1) BLP; 2) MCT; and combination therapy (BLP and MCT). The investigators will assess physiological parameters (number of acne lesions, amount of sebum produced, degree of acne severity) and psychosocial factors (dermatologic quality of life, social anxiety, depressive symptomatology, self-esteem). Participants will complete a baseline assessment prior to initiating treatment and a follow-up assessment at 4 weeks post termination of treatment. The investigators will conduct intermediary assessments at weeks 3 and 5 and 1 week post termination of the treatment. The investigators will use measures of central tendency to describe the sample and repeated measures analysis of variance to compute the main and interaction effects.
Condition: Acne, Acne Vulgaris |
Minimum Age: 18 Years
Status: Terminated |
Phase: Not Applicable
First Posted: April 21, 2015 | Last Updated: February 13, 2020
Study Completion Date: May 12, 2017
Learn More
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
The study will assess safety and tolerability of different doses of topical gel containing a new chemical entity, NVN1000, and the vehicle (gel without drug) applied to the face of healthy volunteers with high counts of Propionibacterium acnes. The test product will be applied once daily for 4 weeks. Exploratory measures include whether the topical product decreases the amount of a bacteria associated with acne (P. acnes).
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: September 25, 2012 | Last Updated: January 28, 2020
Study Completion Date: November 30, 2012
Learn More
Comparison of 1550nm Fractional Laser Alone Versus in Combination With Microneedling for the Treatment of Acne Scars
Acne scarring is an unfortunate consequence of inflammatory acne vulgaris that often leads to significant cosmetic and psychosocial impacts. Although there have been many advances in the treatment of acne scarring, it remains one of the greatest challenges in cosmetic and laser dermatology.
There have been a multitude of studies establishing the efficacy of non-ablative fractional laser therapy for the treatment of atrophic acne scars, and it is widely regarded as one of the best available treatments. More recently, there has been a renewed interest in controlled, non-thermal dermal injury via microneedling devices in the treatment of atrophic acne scars.
Where there is a gap in the literature, however, is in the evaluation of the combination of non-ablative fractional laser resurfacing with microneedling in the treatment of atrophic acne scars.
The investigators' study will compare the safety and efficacy of using non-ablative fractional laser versus a combination of microneedling and non-ablative fractional laser for atrophic acne scars using a randomized, double-blind, split-face study.
The investigators' aim is to further elucidate the pathogenesis of acne scarring and the best approaches for treatment. In doing so, the investigators will study a combination approach to this complex problem in order to better serve future patients.
Condition: Acne Scars |
Minimum Age: 18 Years
Status: Unknown status |
Phase: Not Applicable
First Posted: March 26, 2019 | Last Updated: January 27, 2020
Study Completion Date: December 31, 2020
Learn More
Preoperative Jumpstart for Decolonization of P. Acnes
The objective of the study is to evaluate the efficacy of preoperative treatment with a novel, wireless, low-level microcurrent-generating antimicrobial device (brand name: JumpStart) in preventing the spread of Propionibacterium acnes in patients receiving open or arthroscopic shoulder surgery.
Condition: Shoulder Arthropathy Associated With Other Conditions |
Minimum Age: 18 Years
Status: Terminated |
Phase: Not Applicable
First Posted: March 09, 2018 | Last Updated: January 02, 2020
Study Completion Date: August 01, 2019
Learn More
Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo
The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.
Condition: Acne |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: November 16, 2010 | Last Updated: December 28, 2019
Study Completion Date: October 31, 2010
Learn More
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severity Score [EGSS] of 3 [moderate] or 4 [severe]).
Condition: Acne |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: October 11, 2016 | Last Updated: December 16, 2019
Study Completion Date: February 22, 2017
Learn More
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severity Score [EGSS] of 3 [moderate] or 4 [severe]).
Condition: Acne |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: October 11, 2016 | Last Updated: December 16, 2019
Study Completion Date: February 23, 2017
Learn More
Comparison of 1,550-nm Laser and Fractional Radiofrequency Microneedle for the Treatment of Acne Scars in Ethnic Skin
The primary objective of this randomized, split-face, controlled study is to compare the efficacy and safety of a erbium-doped 1,550-nm non-ablative fractional laser and a bipolar fractional radiofrequency microneedle device for the treatment of atrophic facial acne scars in ethnic skin (Fitzpatrick Skin Phototypes III-VI).
The hypothesis of this study is that both erbium-doped 1,550-nm non-ablative fractional laser and the bipolar fractional radiofrequency microneedle device are equally effective for the treatment of atrophic acne scars in ethnic skin (SPT III-VI). However, the bipolar fractional radiofrequency microneedle device has less adverse effects than erbium-doped 1,550-nm non-ablative fractional laser due to the absence of scattering and the absence of chromophore-specific targets - predominantly melanin - traditionally needed with laser treatments; hence the fractional radiofrequency microneedle device will have a higher safety profile in darker skin types .
Condition: Acne Scars |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: December 08, 2017 | Last Updated: November 17, 2019
Study Completion Date: October 30, 2018
Learn More
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: July 11, 2014 | Last Updated: November 12, 2019
Study Completion Date: February 23, 2017
Learn More
Acne Scarring in Skin of Color: Laser vs Microneedling
Atrophic acne scars are a common and important sequelae of acne that affect up to 43-55% of patients with acne. Scarring impacts quality of life with reports of diminished self-esteem and frustration/sadness; additionally, some individuals report that their appearance even interferes with their professional lives. Though many treatments for acne scarring exist including ablative and nonablative lasers, subcision, and peels, none is without risk of adverse effects of pain, post-procedure redness or pigmentary changes. There have been no randomized studies directly comparing the effectiveness and safety profiles of microneedling (Dermapen) to 1,540nm nonablative fractional lasers (Palomar StarLux) in the treatment of atrophic acne scarring in skin of color. This clinical trial aims to determine which treatment modality -- microneedling or nonablative fractional laser -- is safer and more efficacious in the treatment of acne scarring in patients with skin of color.
Condition: Acne Vulgaris, Scar |
Minimum Age: 18 Years
Status: Withdrawn |
Phase: Not Applicable
First Posted: January 04, 2018 | Last Updated: November 11, 2019
Study Completion Date: December 31, 2020
Learn More
Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.
This single-center clinical study is being conducted over the course of 2 weeks to conduct an exploratory pilot study as a preliminary evaluation of D-OCT's ability to measure skin changes from aging. Assess structural differences between young and aged skin on the face. To identify the structural characteristics of atrophic acne scars relative to normal skin on the face. To explore characteristics of cellulite relative to normal skin on the thigh in young and aged skin.
Condition: Skin Care |
Minimum Age: 18 Years
Status: Completed |
Phase:
First Posted: December 05, 2018 | Last Updated: October 29, 2019
Study Completion Date: July 30, 2019
Learn More
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: September 18, 2015 | Last Updated: October 28, 2019
Study Completion Date: May 12, 2017
Learn More
Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: October 01, 2015 | Last Updated: October 28, 2019
Study Completion Date: November 14, 2017
Learn More
Topical Treatment and Prevalence of P. Acnes
This study is about preventing surgical site infections of the shoulder. We hope to learn if clindamycin alone, benzoyl peroxide alone, or clindamycin and benzoyl peroxide together can affect growth of Propionibacterium acnes in the dermal layer.
Condition: Surgical Site Infection |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: August 01, 2017 | Last Updated: October 25, 2019
Study Completion Date: January 01, 2018
Learn More
Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction
The purpose of this study is to determine whether Artefill is safe and effective for the correction of atrophic facial acne scars.
Condition: Atrophic Acne Scar |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 3
First Posted: March 15, 2012 | Last Updated: October 21, 2019
Study Completion Date: February 28, 2014
Learn More
A Pilot Study to Evaluate the Safety and Effectiveness of Microneedling and Bellafill to Treat Facial Acne Scars
This is an open-label, randomized, multicenter, prospective trial assessing the efficacy and safety of microneedling treatment alone vs. microneedling treatment followed by treatment with Bellafill for correction of distensible atrophic facial acne scars.
Condition: Atrophic Acne Scars |
Minimum Age: 21 Years
Status: Completed |
Phase: Not Applicable
First Posted: December 29, 2015 | Last Updated: October 21, 2019
Study Completion Date: June 05, 2017
Learn More
Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel
This will be an open-label study designed to assess the safety and plasma PK of topically applied IDP-126 Gel compared to Control Gel.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 1
First Posted: August 20, 2018 | Last Updated: October 18, 2019
Study Completion Date: June 19, 2019
Learn More
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
This study is to evaluate the therapeutic equivalence and safety of Taro Product to RLD in the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 1
First Posted: October 18, 2019 | Last Updated: October 18, 2019
Study Completion Date: October 15, 2019
Learn More
A Study of a New Drug Treatment for Acne
A study to determine if three different doses of a new acne treatment are safe and better at reducing facial acne than a treatment without active ingredient.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: March 30, 2011 | Last Updated: October 02, 2019
Study Completion Date: March 31, 2012
Learn More
Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris
The purpose of this study is to determine the response of acne patients and healthy control patients to the P. acnes bacteria. Half a tube of blood will be drawn from all participants to determine whether or not they have antibodies to the P. acnes bacterium. Anywhere from 1 to 4 skin biopsies of acne pimples or normal control skin will be taken from all subjects for further analysis in the lab to determine whether the inflammation in these pimples can be reduced using anti-P.acnes antibodies.
Condition: Acne |
Minimum Age: 18 Years
Status: Completed |
Phase:
First Posted: August 21, 2013 | Last Updated: October 02, 2019
Study Completion Date: June 30, 2014
Learn More
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
Prospective, randomized, controlled, parallel group clinical study with blinded assessment evaluating Sebacia Microparticles (SM) with Nd:Yag laser in facial inflammatory acne vulgaris
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Not Applicable
First Posted: October 02, 2017 | Last Updated: October 02, 2019
Study Completion Date: April 10, 2018
Learn More
Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Dose-ranging Study in the Treatment of Acne Vulgaris,
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Unknown status |
Phase: Phase 2
First Posted: April 01, 2019 | Last Updated: September 30, 2019
Study Completion Date: March 31, 2020
Learn More
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
The purpose of this study is to evaluate the superiority in efficacy and assess safety and tolerability of the products S6G5T-3 and S6G5T-1 as compared to their respective active components or the vehicle for the treatment of acne.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 2
First Posted: January 11, 2016 | Last Updated: September 18, 2019
Study Completion Date: October 31, 2017
Learn More
Reduced Side-Effects Of Photodynamic Therapy For The Treatment Of Moderate To Severe Acne (i-PDT)
This research study aims to compare different methods for helping difficult to treat or scarring (cystic) acne, ALA-PDT and i-PDT.
There is an investigational procedure called photodynamic therapy (ALA-PDT) that has been reported to be very efficient for acne treatment since 2000. Photodynamic therapy (PDT) uses a drug called ALA (aminolevulinic acid), which is marketed as Levulan®.
Levulan® is applied directly to facial/back acne. This is the way that it is usually applied. Levulan® is left on the skin for three hours so the skin can absorb it. Next, the skin where the Levulan® was applied is exposed to a red light for activation.
The sebaceous glands get obstructed and inflamed causing acne. ALA gets down under your skin through the skin pores to where the glands are. PDT destroys the glands reducing the acne lesion.
Levulan® is absorbed by normal skin surrounding the oil glands. Therefore, this procedure also has some side effects. Some of the side effects include pain, burning sensation during the procedure, and redness, tenderness, and swelling after the procedure.
At Massachusetts General Hospital's Wellman Center for Photomedicine, the investigators developed another procedure called inhibitory-PDT (i-PDT) that is similar to ALA-PDT. i-PDT is aimed at reducing the side-effects of ALA- PDT.
The difference between these two procedures is that i-PDT uses a light source that will prevent Levulan® accumulation in the normal skin surface. The investigators would like to find out if Levulan® will be placed only inside the sebaceous glands.
Condition: Acne Vulgaris |
Minimum Age: 14 Years
Status: Completed |
Phase: Phase 1
First Posted: October 05, 2011 | Last Updated: September 17, 2019
Study Completion Date: December 31, 2014
Learn More
"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"
The purpose of this study is to determine whether an automated electronic reminder system using text messages sent to patient's cell phones will help patients with acne be more compliant with their topical medications and lead to an improvement of their acne.
Hypothesis: Automatically delivered electronic reminders in the form of text messages will increase acne patient adherence to topical medications and consequently result in better treatment outcome and higher patient satisfaction
Condition: Acne, Patient Compliance |
Minimum Age: 12 Years
Status: Completed |
Phase: Not Applicable
First Posted: March 05, 2010 | Last Updated: September 13, 2019
Study Completion Date: October 31, 2010
Learn More
A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers
A Phase I, Single-Center, Open-Label, Randomized, Parallel Group, 3 Day Study Evaluating the Safety and Cutaneous Tolerability of NVN1000 Topical Gel in Healthy Volunteers
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: December 18, 2012 | Last Updated: September 09, 2019
Study Completion Date: December 31, 2012
Learn More
Propionibacterium Acnes in Shoulder Arthroplasty
The investigator's plan to determine whether pre-operative skin preparation with hydrogen peroxide alters rates of P acnes culture positivity. They hypothesize that pre-operative skin preparation with hydrogen peroxide will reduce rates of P acnes culture positivity.
Condition: Propionibacterium Acnes |
Minimum Age: 40 Years
Status: Completed |
Phase: Not Applicable
First Posted: February 14, 2017 | Last Updated: August 29, 2019
Study Completion Date: March 31, 2019
Learn More
Comparing OTC Acne Treatment to Prescription Regimen
This research is being done to find out the safety and efficacy of two acne creams, Effaclar and Benzaclin when used twice daily with a topical retinoid. Effaclar and Benzaclin are FDA approved for the treatment of acne.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: November 09, 2010 | Last Updated: June 27, 2019
Study Completion Date: October 31, 2011
Learn More
A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris
UHE-101 cream, 1% ("UHE-101") is being developed for the topical treatment of acne vulgaris. The purpose of this study is to compare the safety and efficacy of twice daily topical application of UHE-101 cream for 12 weeks to its vehicle cream in subjects with facial acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: October 05, 2017 | Last Updated: May 17, 2019
Study Completion Date: May 31, 2018
Learn More
P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne
This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: January 26, 2016 | Last Updated: May 10, 2019
Study Completion Date: December 09, 2016
Learn More
Restylane Silk Acne Scar Efficacy Evaluation Study
Randomized, double-blind, placebo-controlled, research pilot study. 30 subjects aged 22-55 years old of all skin types will be asked to sign an informed consent form prior to any study procedures. Subjects must have at least 1 but up to 3 acne scars ≥3 mm or ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Restylane® Silk or Placebo) in each scar at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will be asked to come to 10 visits: Screening visit (up to 35 days prior to Baseline), Baseline (Day 0), Day 7, Day 14, Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6 (study exit visit). The treatment area will be evaluated at each visit by the unblinded investigator regarding erythema, bruising, inflammation, itching, stinging/burning, brightness, fullness, smoothness, and clarity. Safety and adverse events will be captured at each visit only by the unblinded investigator.
Condition: Acne, Acne Scars, AdverseEvent |
Minimum Age: 22 Years
Status: Terminated |
Phase: Not Applicable
First Posted: November 02, 2016 | Last Updated: May 08, 2019
Study Completion Date: April 18, 2019
Learn More
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
To evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% (Aleor Dermaceuticals Limited, India) and Differin® (Adapalene) Gel 0.3% (Galderma Laboratories, LP USA) in the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: August 26, 2018 | Last Updated: April 24, 2019
Study Completion Date: February 16, 2019
Learn More
"Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy"
The purpose of this study is to study the effects of topical Vitamin D cream (Calcipotriene, also known as Dovonex) on acne. The information gained from this study may lead to new treatments for acne. In this study, Calcipotriene will be compared with a placebo, a cream that looks like Calcipotriene, but contains no active ingredients.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2/Phase 3
First Posted: September 24, 2012 | Last Updated: April 18, 2019
Study Completion Date: January 09, 2014
Learn More
Effects of Omega-3 Fatty Acid Supplementation in Acne Patients
60 patients receiving isotretinoin will be recruited from the UCLA acne specialty clinic. Subjects will be randomized in a 1:1 ratio to receive placebo or omega-3 1200mg twice a day for 24 weeks.
Condition: Acne |
Minimum Age: 18 Years
Status: Terminated |
Phase: Phase 3
First Posted: January 07, 2013 | Last Updated: April 15, 2019
Study Completion Date: March 31, 2019
Learn More
Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of dapsone in subjects with acne vulgaris following 28 days of dosing.
Condition: Acne Vulgaris |
Minimum Age: 16 Years
Status: Completed |
Phase: Phase 1
First Posted: January 18, 2013 | Last Updated: April 11, 2019
Study Completion Date: May 05, 2013
Learn More
Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris
To determine if Dapsone (Aczone) 7.5% gel is a safe and effective treatment for acne on the trunk
Condition: Acne |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: October 04, 2016 | Last Updated: March 20, 2019
Study Completion Date: September 11, 2017
Learn More
The Use of Oracea and Epiduo Forte in Severe Acne Patients
This is a single-center, open label pilot study. The study is comprised of 5 study visits; Screening, Baseline, and weeks 4, 8, and 12. All subjects will receive Oracea once daily (QD) and Epiduo Forte at Baseline. We will evaluate Investigator Global Assessment (IGA), total lesion count, inflammatory lesion count, non-inflammatory lesion count, adverse events and concomitant medications.
Condition: Acne |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: February 27, 2018 | Last Updated: March 20, 2019
Study Completion Date: January 04, 2019
Learn More
The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
This is a single-center, open label pilot study. The study is comprised of 5 study visits; Screening, Baseline, and Weeks 4, 8, and 16. All subjects will receive Onexton at Baseline and be instructed to apply the gel once daily to the face. The investigators will evaluate Investigator Global Assessment of acne (IGA), total lesion count, inflammatory lesion count, non-inflammatory lesion count, Investigator Global Assessment of Post-Inflammatory Hyperpigmentation and distribution of Post-Inflammatory Hyperpigmentation, adverse events and concomitant medications.
Condition: Acne Vulgaris, Post Inflammatory Hyperpigmentation |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: January 11, 2018 | Last Updated: March 19, 2019
Study Completion Date: February 28, 2018
Learn More
A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne
This is a 12 week, multi-site, double-blind, vehicle-controlled study in subjects with mild to moderate facial acne. Subjects will be randomized 1:1 to apply either topical NAG or vehicle gel daily. Subjects will be evaluated for clinical acne and quality of life outcomes at baseline, 2 weeks, 4 weeks, 8 weeks and 12 weeks.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 1/Phase 2
First Posted: March 13, 2015 | Last Updated: March 07, 2019
Study Completion Date: September 30, 2015
Learn More
Long-term Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA
This study evaluates the safety, effectiveness, and maintenance of effect of a novel topical silver particle solution (Sienna 755.1100, 810.1100, or 1064.1100) used in conjunction with a laser for the treatment of Acne Vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase:
First Posted: January 25, 2017 | Last Updated: February 28, 2019
Study Completion Date: May 31, 2018
Learn More
Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne
An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of LEO 43204 in adults with moderate to severe acne.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: October 13, 2015 | Last Updated: February 26, 2019
Study Completion Date: April 30, 2017
Learn More
Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris
The investigators conducted a recent pilot study and found a strong positive correlation between the consumption of 100% chocolate and acne exacerbation. However, this study had limitations including the lack of placebo and the small sample size. Although studies have been conducted assessing chocolate's effect on acne, no study has been done evaluating this effect using chocolate with 100% cocoa content in a double blind placebo controlled fashion. This study will analyze the difference in the number and type of acneiform lesions per subject at the different time points (Day 4 and Day 7) compared to baseline in order to increase the validity of the investigators results. In addition, the investigators will use unsweetened cocoa powder,12 rather than chocolate candy, which contains higher quantities of additive ingredients such as sugar and milk to avoid interference with the results and the possibility to establish or not an association between the unsweetened cocoa and an effect on acne.
Condition: Acne |
Minimum Age: 18 Years
Status: Terminated |
Phase: Not Applicable
First Posted: September 01, 2010 | Last Updated: February 18, 2019
Study Completion Date: July 31, 2012
Learn More
A Study to Evaluate the Efficacy and Tolerance of 2 Acne Treatment Regimens on Subjects With Mild to Moderate Acne
This study will compare two different acne treatment regimens for the treatment of acne. Half of participants will receive a cleanser and a light therapy mask, while half of the participants will receive a cleanser, a light therapy topical gel-cream, and a light therapy mask.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Not Applicable
First Posted: April 03, 2017 | Last Updated: February 13, 2019
Study Completion Date: September 06, 2017
Learn More
Potential Research Study Participant Registry
The purpose of the potential research study participant registry is to keep potential research subjects informed about any future research studies in which they may meet the criteria for enrollment. The purpose of this study is also to assist current and future clinical trials with recruitment of subjects.
Condition: Acne, Actinic Keratosis, Atopic Dermatitis, Dysplastic Nevi, Eczema, Foot Ulcers, Leg Ulcers, Psoriasis, Rosacea, Skin Cancer |
Minimum Age: 18 Years
Status: Completed |
Phase:
First Posted: July 02, 2008 | Last Updated: February 12, 2019
Study Completion Date: September 05, 2018
Learn More
Finasteride Treatment of Severe Nodulocystic Acne
Double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of once weekly, high dose oral finasteride compared to placebo for the treatment of severe nodulocystic acne in male subjects.
Condition: NODULOCYSTIC ACNE |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: July 10, 2015 | Last Updated: February 12, 2019
Study Completion Date: June 06, 2017
Learn More
Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris
To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: June 22, 2012 | Last Updated: January 31, 2019
Study Completion Date: January 31, 2013
Learn More
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: December 15, 2014 | Last Updated: January 31, 2019
Study Completion Date: February 01, 2017
Learn More
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
To evaluate the efficacy and safety of an approximate 1.5 mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: December 15, 2014 | Last Updated: January 31, 2019
Study Completion Date: January 12, 2017
Learn More
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral sarecycline in the long-term treatment of participants with moderate to severe facial acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 3
First Posted: April 02, 2015 | Last Updated: January 31, 2019
Study Completion Date: August 26, 2016
Learn More
A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel
This is a 2 week Phase 1 study of SB204 (NVN1000 Gel) in healthy adult volunteers with elevated Propionibacterium acnes (P. acnes) counts. Subjects will apply NVN1000 4% Gel or Vehicle Gel twice daily to their face. Assessments will include cutaneous tolerability, safety, and P. acnes counts.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: April 29, 2013 | Last Updated: November 15, 2018
Study Completion Date: June 30, 2013
Learn More
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
In this study, color (erythema) and pH will be measured on 3 consecutive days after application of 2 doses of SB204 to the cheeks of healthy volunteers.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: September 10, 2014 | Last Updated: November 15, 2018
Study Completion Date: September 30, 2014
Learn More
A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
A Double-Blind, Double-Dummy, Randomized, 4-Period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: October 15, 2015 | Last Updated: November 15, 2018
Study Completion Date: April 30, 2016
Learn More
Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris
A Phase 1, Single-center, Open-label, Pharmacokinetic, Safety and Tolerability Study of SB204 in Adolescents with Moderate to Severe Acne Vulgaris
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 1
First Posted: June 09, 2016 | Last Updated: October 10, 2018
Study Completion Date: August 25, 2016
Learn More
A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: October 28, 2013 | Last Updated: October 05, 2018
Study Completion Date: October 31, 2014
Learn More
Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: October 28, 2013 | Last Updated: October 05, 2018
Study Completion Date: October 31, 2014
Learn More
Does the Addition of Hydrogen Peroxide to Chlorhexidine Skin Prep to Treat P. Acnes in the Shoulder
This is a prospective, randomized controlled trial to evaluate the ability of hydrogen peroxide preparation in addition to chlorhexidine to decrease the colonization of Propionibacterium acnes(a bacteria commonly found in the dermis of the skin surrounding the shoulder in order to decrease postoperative joint infection.
Condition: Propionibacterium Infection |
Minimum Age: 18 Years
Status: Unknown status |
Phase: Not Applicable
First Posted: August 23, 2018 | Last Updated: August 31, 2018
Study Completion Date: February 28, 2019
Learn More
A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
The study will look to evaluate the tolerance of a light therapy-based acne mask device in participants who report having sensitive skin. All participants will receive a cleanser, a light therapy mask, and an extra activator for the light therapy mask.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Not Applicable
First Posted: April 20, 2017 | Last Updated: August 30, 2018
Study Completion Date: June 08, 2017
Learn More
A Novel Method to Improve Acne Outcomes
This is an investigator-blinded, prospective study of 20 subjects aged 13 through 18 with mild to moderate acne. Study subjects will be randomized to an internet survey group, in which an email link for a survey ascertaining the status of the subject's acne is sent weekly, or to a control group. All study subjects will use benzoyl peroxide 5% gel, and adherence and clinical improvement will be monitored over 12 weeks. The investigators hypothesis is that subjects in the internet survey group will have improved adherence to the study medication and clinical outcomes, because the weekly survey will remind subjects to use their medication.
Condition: Acne Vulgaris |
Minimum Age: 13 Years
Status: Completed |
Phase: Not Applicable
First Posted: August 05, 2010 | Last Updated: August 14, 2018
Study Completion Date: August 31, 2010
Learn More
Effect of Samples on Acne Treatment With Epiduo® Gel
The purpose of this study is to compare adherence to treatment and efficacy with Epiduo® Gel in patients with mild to moderate acne who receive a medication sample and instructions on proper application with their stock size medication tube versus patients who receive only the stock size medication tube.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: December 28, 2011 | Last Updated: August 13, 2018
Study Completion Date: November 30, 2012
Learn More
Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris
The primary objective of this study is to investigate potential differences between four treatment intervention groups in the adherence to treatment with Differin® Gel, 0.1%. Differin is approved by the Food and Drug Administration (FDA) to treat acne.
Condition: Acne Vulgaris |
Minimum Age: 13 Years
Status: Completed |
Phase: Phase 4
First Posted: June 09, 2008 | Last Updated: August 09, 2018
Study Completion Date: October 31, 2009
Learn More
Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris
The purpose of this research study is to evaluate the effectiveness of two different types of topical acne medication. This study will help to determine if one combined medication results in better acne improvement than two separate medications for acne.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: January 11, 2010 | Last Updated: August 09, 2018
Study Completion Date: October 31, 2009
Learn More
Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne
The purpose of this research study is to see how often benzoyl peroxide is applied for acne. Use of medication was monitored electronically.
Condition: Acne Vulgaris |
Minimum Age: 13 Years
Status: Completed |
Phase: Phase 4
First Posted: April 09, 2008 | Last Updated: July 30, 2018
Study Completion Date: May 31, 2008
Learn More
Treatment of Acne Scars With Erbium:Yttrium Aluminum Garnet (Er:YAG) Laser Examined Under OCT
This study is examining the effects of the 2940 nm Er:YAG on atrophic facial acne scars under optical coherence tomography in terms of blood flow, vessel shape, skin roughness, collagen content, and epidermal thickness.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Withdrawn |
Phase: Not Applicable
First Posted: August 01, 2017 | Last Updated: July 24, 2018
Study Completion Date: December 31, 2018
Learn More
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: August 29, 2016 | Last Updated: July 19, 2018
Study Completion Date: May 31, 2017
Learn More
Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream
The Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison with Tazorac Cream.
Condition: Acne |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 1
First Posted: July 06, 2016 | Last Updated: July 17, 2018
Study Completion Date: January 31, 2017
Learn More
Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris
To see if teledermatology can be used to reduce antibiotic burden in patients on doxycycline or minocycline for acne vulgaris
Condition: Acne Vulgaris |
Minimum Age: 15 Years
Status: Completed |
Phase: Not Applicable
First Posted: June 09, 2016 | Last Updated: June 28, 2018
Study Completion Date: May 31, 2018
Learn More
Safety and Efficacy of the Use of Botox on Acne
• To determine the safety and efficacy of Botox Treatment in subjects with mild to moderate acne vulgaris defined by the Investigator's Global Assessment (IGA)
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Terminated |
Phase: Phase 2
First Posted: September 30, 2008 | Last Updated: May 30, 2018
Study Completion Date: December 31, 2008
Learn More
Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris
The study hypothesis are based on the assumption that :
CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical Gel Vehicle in the overall population and in the subgroup of severe Subjects
CD0271 0.3%/CD1579 2.5% Gel applied once daily for up to 12 weeks has an acceptable safety and tolerability profile
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: June 14, 2013 | Last Updated: May 28, 2018
Study Completion Date: March 31, 2014
Learn More
Can Addition of Doxycycline Perioperatively Reduce Propionibacterium Acnes in Shoulder Arthroplasty?
The purpose of this study is to investigate antibiotic treatment to target bacteria about the shoulder. This bacteria, Propionibacterium acnes, is detected in many revision shoulder surgeries and is thought to contribute to periprosthetic joint infections, pain, and failure of total shoulder arthroplasty as well as other shoulder surgeries. This study is investigating adding an FDA approved antibiotic that is commonly used for treatment of this bacteria and many common infections. The investigators will take intraoperative cultures to look for the presence or absence of specific bacteria. The investigators are conducting this trial to see if adding another antibiotic to specifically target this common bacteria found around the shoulder will be effective.
Condition: Osteoarthritis |
Minimum Age: 40 Years
Status: Completed |
Phase: Not Applicable
First Posted: April 25, 2016 | Last Updated: May 16, 2018
Study Completion Date: February 28, 2017
Learn More
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris
Bioequivalence study comparing Tretinoin Cream, 0.1% to RETIN-A®.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Early Phase 1
First Posted: January 29, 2018 | Last Updated: May 16, 2018
Study Completion Date: January 26, 2018
Learn More
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris
Bioequivalence study comparing Tretinoin Cream, 0.05% to RETIN-A®.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Early Phase 1
First Posted: January 29, 2018 | Last Updated: May 16, 2018
Study Completion Date: January 26, 2018
Learn More
Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne
The primary objective of this study is to compare the efficacy and safety and tolerability of ACYC Gel and vehicle in the treatment of subjects with Acne Vulgaris.
Condition: Acne |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: September 27, 2012 | Last Updated: May 02, 2018
Study Completion Date: July 31, 2013
Learn More
DMT210 Topical Gel in the Treatment of Acne Rosacea
The study evaluates the safety, tolerability, and efficacy of DMT210 Gel, 5% when applied twice daily for 12 weeks in adult patients with moderate to severe acne rosacea. Half of participants will receive DMT210 Gel while the other half will receive vehicle control.
Condition: Acne Rosacea |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: December 20, 2016 | Last Updated: April 17, 2018
Study Completion Date: August 30, 2017
Learn More
enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars
The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm Nd:YAG picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece attachment for improvement of acne scars.
Condition: Acne Scars - Mixed Atrophic and Hypertrophic |
Minimum Age: 18 Years
Status: Unknown status |
Phase: Not Applicable
First Posted: September 11, 2017 | Last Updated: March 13, 2018
Study Completion Date: September 30, 2018
Learn More
Cultural Differences in Treatment Preferences and Perceptions of Acne
This study will use a survey to examine relationships between culture, race, and ethnicity with treatment preferences and perceptions for acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase:
First Posted: June 15, 2017 | Last Updated: March 02, 2018
Study Completion Date: February 28, 2018
Learn More
Evaluation of the Cutera Enlighten™ Laser With Micro-Lens Array (MLA) Handpiece Attachment
The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm Nd:YAG picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece attachment for improvement of moderate to severe acne scars.
Condition: Acne, Scarring |
Minimum Age: 18 Years
Status: Unknown status |
Phase: Not Applicable
First Posted: February 01, 2018 | Last Updated: February 06, 2018
Study Completion Date: December 31, 2018
Learn More
Comparison of Two Salicylic Acid Formulations
This study is a split face, paired-comparison, pilot study of at least 10 subjects to complete. Participants in this study will be patients seen at Children's Memorial Hospital, who are clinically diagnosed with mild to moderate acne vulgaris. Participants will be recruited from one of the clinics, as well as from previous Institutional Review Board (IRB) approved acne studies housed in the Department of Dermatology. All subjects accrued from previous studies have agreed to be contacted for further investigations. Subjects 13 to 35 years of age with mild to moderate acne vulgaris symmetrical in appearance on both sides of the face, and meeting inclusion criteria will be eligible to participate
Condition: Acne Vulgaris |
Minimum Age: 13 Years
Status: Completed |
Phase: Not Applicable
First Posted: November 24, 2008 | Last Updated: January 31, 2018
Study Completion Date: August 31, 2008
Learn More
A Study to Evaluate the Effectiveness and Tolerance of Two Acne Treatments on Subjects With Mild to Moderate Acne.
This study will compare two different acne treatments for the treatment of acne. Half of the participants will receive two marketed acne products (cleanser and leave-on topical treatment), while the other half of the participants will receive a marketed cleanser and a light-therapy device.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Not Applicable
First Posted: February 26, 2016 | Last Updated: December 27, 2017
Study Completion Date: August 31, 2016
Learn More
Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 2
First Posted: May 06, 2016 | Last Updated: December 14, 2017
Study Completion Date: September 30, 2016
Learn More
Ultherapy® for the Treatment of Acne Scars
This is a prospective, multi-site trial to be conducted at 2 clinical sites. Up to 20 subjects will receive study treatments. Following study treatments, follow-up visits will occur at 60, 90 and 180 days from each subject's last study treatment.
Condition: Acne Scars, Atrophic Acne Scars |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: May 20, 2014 | Last Updated: December 13, 2017
Study Completion Date: October 31, 2015
Learn More
Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris
Open-Label study designed to assess the safety and plasma PK of tretinoin and relevant metabolites after topical dermal application of IDP-121 lotion.
Condition: Acne |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 1
First Posted: July 06, 2016 | Last Updated: December 12, 2017
Study Completion Date: October 31, 2016
Learn More
Feasibility Study: Ulthera® System for the Treatment of Moderate to Severe Facial Acne
This study will evaluate the effectiveness of Ultherapy for the treatment of facial acne.
Condition: Facial Acne |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: April 27, 2012 | Last Updated: November 21, 2017
Study Completion Date: July 31, 2014
Learn More
Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel
Study designed to assess the safety and plasma PK of tretinoin and its metabolites from topically applied IDP-120 gel.
Condition: Acne |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 1
First Posted: July 06, 2016 | Last Updated: September 20, 2017
Study Completion Date: November 30, 2016
Learn More
Safety Study of Plasma Treatment System to Treat Back Acne
The purpose of this study is to evaluate the safety of treating human skin with atmospheric plasma and get an initial evaluation of the efficacy of this treatment for acne.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Terminated |
Phase: Not Applicable
First Posted: August 02, 2012 | Last Updated: September 12, 2017
Study Completion Date: June 30, 2013
Learn More
Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris
Prospective, randomized multicenter study to examine the safety and effectiveness of Sebacia microparticles with or without laser in the treatment of moderate to moderately-severe inflammatory acne vulgaris
Condition: Inflammatory Acne Vulgaris |
Minimum Age: 15 Years
Status: Completed |
Phase: Not Applicable
First Posted: August 11, 2014 | Last Updated: September 08, 2017
Study Completion Date: December 31, 2015
Learn More
Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris
The purpose of this study is to compare the efficacy of a benzoyl peroxide 2.5% cream formulation plus a moisturizing lotion versus benzoyl peroxide 2.5% cream alone for the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: November 13, 2007 | Last Updated: August 28, 2017
Study Completion Date: January 31, 2008
Learn More
Six Months Evaluation of Next Science Acne Creams on Facial Acne in Adult Females.
To assess facial acne vulgaris clinical and psychological outcomes by measuring differences in lesions counts, investigator global assessment, and subjects quality of life scores over 6 months in adult females treated with Next Science™ acne cream 2x or Next Science™ acne cream 1x in a double blind manner.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Terminated |
Phase: Early Phase 1
First Posted: March 27, 2017 | Last Updated: August 28, 2017
Study Completion Date: August 14, 2017
Learn More
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
The goal of this study is to enroll 250 participants that have joined the MURDOCK Study Horizon 1.5 (Duke IRB Pro00011196) with a current or prior diagnosis of severe acne AND current or prior treatment with oral isotretinoin. All 250 participants will answer a 5-page questionnaire designed to collect information on the diagnosis of severe acne and response to oral isotretinoin treatment. The aim is to identify genetic predictors of severe acne vulgaris and the outcome of oral isotretinoin treatment.
Condition: Acne Vulgaris, Isotretinoin |
Minimum Age: 12 Years
Status: Completed |
Phase:
First Posted: October 24, 2012 | Last Updated: August 23, 2017
Study Completion Date: August 31, 2015
Learn More
Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline
The primary objective of this study is to evaluate the skin and plasma concentrations of minocycline in subjects undergoing treatment of acne vulgaris with oral extended release minocycline. Acne lesion counts and safety/tolerance of the treatment will also be evaluated.
Condition: Acne |
Minimum Age: 14 Years
Status: Completed |
Phase: Phase 4
First Posted: February 18, 2016 | Last Updated: August 16, 2017
Study Completion Date: May 31, 2016
Learn More
BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes
This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate the comparative reduction of Propionibacterium acnes in-vivo following once daily topical administration of BPX-01 Minocycline 1% Topical Gel (BPX-01) or BPX-01 Vehicle control.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: March 10, 2016 | Last Updated: August 16, 2017
Study Completion Date: June 30, 2016
Learn More
A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments
The purpose of this study is to evaluate the efficacy of 2 acne treatments for 24 weeks of use in adult men and women with mild to moderate facial acne, at least 5 inflammatory lesions, and at least 10 - 100 non-inflammatory lesions.
Objective:
To characterize the effectiveness of the acne treatment in lesion count at week 1, week 2, week 6, week 12, and week 24 as compared to baseline and compare between treatments
To characterize the effectiveness of the acne treatment in Investigator's Global Improvement Assessment at week 1, week 2, week 6, week 12, and week 24 as compared to baseline and compare between treatments
To characterize the effect of the acne treatment in clinical grading of efficacy parameters through digital images at week 6, week 12, and week 24 as compared to baseline and compare between treatments
To characterize the effect of the acne treatment in subject self-assessment questionnaire responses at week 1, week 2, week 6, week 12, and week 24 as compared to baseline and compare between treatments
Condition: Acne |
Minimum Age: 21 Years
Status: Completed |
Phase: Phase 4
First Posted: April 18, 2016 | Last Updated: July 31, 2017
Study Completion Date: April 04, 2017
Learn More
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
The objective of the study is to compare the safety and efficacy of multiple formulations of BLI1100 to a control group and placebo in treating patients with moderate-severe acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: November 12, 2015 | Last Updated: July 27, 2017
Study Completion Date: June 30, 2016
Learn More
A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
The purpose of this study is to assess systemic exposure of a new foam formulation of tazarotene, 0.1% compared with Tazorac Gel, 0.1%. The study design and dosing regimen are based on previous clinical studies with Tazorac Gel and Tazorac Cream.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 1
First Posted: November 19, 2009 | Last Updated: June 22, 2017
Study Completion Date: December 20, 2009
Learn More
A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers
The purpose of this study is to evaluate the irritation level of tazarotene foam after 21 days of exposure on the skin of healthy volunteers.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: April 27, 2010 | Last Updated: June 19, 2017
Study Completion Date: April 26, 2010
Learn More
A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
The purpose of this study is to evaluate the potential of Tazarotene Foam to induce a phototoxic reaction when exposed to UV and VIS light on skin of healthy volunteers.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: April 30, 2010 | Last Updated: June 19, 2017
Study Completion Date: April 10, 2010
Learn More
A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers
This study will assess the potential of tazarotene foam to cause sensitization during a 48 hour challenge following 21 days of exposure on the skin of healthy volunteers.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: April 29, 2010 | Last Updated: June 12, 2017
Study Completion Date: June 26, 2010
Learn More
A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
The purpose of this study is to evaluate the potential of Tazarotene Foam to induce a photoallergic reaction when exposed to UV and VIS light on skin of healthy volunteers.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: May 05, 2010 | Last Updated: June 12, 2017
Study Completion Date: June 26, 2010
Learn More
To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.
This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1%/ Benzoyl peroxide 5% topical gel (Glenmark Generics, Ltd), and the marketed product BenzaClin® Topical Gel, Clindamycin 1%/ Benzoyl peroxide 5% (Valeant Pharmaceuticals, US) in the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: June 04, 2015 | Last Updated: May 26, 2017
Study Completion Date: December 31, 2015
Learn More
A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel
The purpose of this study is to demonstrate the safety and effectiveness of CT Gel in subjects with acne vulgaris. The hypothesis is that CT Gel is superior to Clindamycin Gel, Tretinoin Gel and Vehicle Gel for the treatment of acne vulgaris.
Condition: Acne, Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: May 24, 2008 | Last Updated: May 25, 2017
Study Completion Date: May 31, 2009
Learn More
Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications
This is a randomized, half-face study. On 1 side of the face, the subject will apply 1 of the 2 test products, clindamycin and benzoyl peroxide or dapsone gel and the contra lateral side of the face will remain non-treated to serve as a control.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: August 20, 2009 | Last Updated: May 25, 2017
Study Completion Date: August 31, 2009
Learn More
The Lipid Profile of the Skin Surface in Acne
The purpose of this study is to evaluate the differences in the skin lipid profile of patients with and without acne. Secondly, the goal is to learn more about what the effects of retinoinds (topical and systemic) are on the the skin lipid profile. We hypothesize that the skin lipid profile of subjects with acne will be lower in inflammatory lipids in comparison to subjects without acne.
Condition: Acne |
Minimum Age: 12 Years
Status: Completed |
Phase:
First Posted: June 30, 2014 | Last Updated: May 25, 2017
Study Completion Date: July 31, 2015
Learn More
Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne
To compare the efficacy and safety of Benzoyl peroxide used in combination with clindamycin vs. Benzoyl peroxide used in combination with clindamycin and doxycycline in the treatment of moderate acne
Condition: Acne |
Minimum Age: 16 Years
Status: Completed |
Phase: Phase 4
First Posted: February 04, 2009 | Last Updated: May 24, 2017
Study Completion Date: August 31, 2008
Learn More
Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne
The purpose of the study is to determine the development of microbial resistance when using one of two topical acne therapies for the treatment of facial acne vulgaris.
Condition: Acne |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: February 10, 2009 | Last Updated: May 24, 2017
Study Completion Date: January 31, 2009
Learn More
A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash
The purpose of this study is to evaluate the tolerability of a combined regimen of a topical antibiotic and retinoid and a benzoyl peroxide wash.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: April 29, 2009 | Last Updated: May 19, 2017
Study Completion Date: June 05, 2009
Learn More
TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris
The purpose of this study is to determine the safety and effectiveness of TSN 2898 topical gel in the treatment of moderate to severe acne.
Condition: Acne Vulgaris |
Minimum Age: 16 Years
Status: Withdrawn |
Phase: Phase 2
First Posted: May 26, 2016 | Last Updated: April 24, 2017
Study Completion Date: February 28, 2017
Learn More
U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne
This study is being conducted to obtain safety, efficacy, and satisfaction data on the combination of topical Benzoyl Peroxide (BPO) 2.5% and the topical keratolytic agent Salicylic Acid (SA) 0.5% in the treatment of moderate to severe acne. Subjects with moderate or severe acne will be asked to apply the commercially available, over-the-counter products Foam Deep Cleanser (2.5% BPO), Foam Advanced Acne Treatment (2.5% BPO), and Foam Rejuvenating Toner (0.5% SA) daily for 12 weeks. No control group or reference treatment will be included.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Not Applicable
First Posted: July 28, 2011 | Last Updated: April 21, 2017
Study Completion Date: December 15, 2011
Learn More
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne
The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: November 19, 2009 | Last Updated: April 17, 2017
Study Completion Date: November 09, 2010
Learn More
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
This is a 12-week, multi-center, double-blind, randomized, three-arm, vehicle-controlled study.
Subjects will be randomized (1:1:1) to 1% or 2 % BPX-01 gel, or vehicle. Subjects will apply 1g of the gel as a thin film to the entire face at least 30 minutes before bedtime each night for 12 weeks. Lesion counts, IGA, and Patient-Reported Outcomes (PGI-S and PGI-I) will be performed to assess efficacy.
Blood draws will be collected at baseline (Day 0), and at Weeks 4 and 12 to evaluate the level of minocycline in plasma. Safety will be assessed with the vital signs, brief physical examination, clinical laboratory tests, cutaneous tolerance score, incidence of minocycline-induced skin hyperpigmentation, incidence of visual disturbances and/or headaches suggestive of pseudotumor cerebri, and collection of adverse events.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 2
First Posted: June 24, 2016 | Last Updated: April 12, 2017
Study Completion Date: March 24, 2017
Learn More
Sebum Collection and Skin Barrier Function Analysis
The goal is this study is to evaluate how the skin surface lipid composition is correlated with overall sebum production, barrier function, and inflammatory disease status. We hypothesize that there will be differences in the skin surface composition among subjects of various groups:
Young vs older healthy population
Atopic dermatitis vs Acne vs Healthy controls
Active smokers vs non-smoker controls
Condition: Acne, Aging, Atopic Dermatitis, Smoking |
Minimum Age: 12 Years
Status: Completed |
Phase:
First Posted: July 10, 2014 | Last Updated: April 07, 2017
Study Completion Date: February 26, 2016
Learn More
A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris
This is a single center, randomized, double-blind, placebo-controlled study in subjects with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1/Phase 2
First Posted: January 11, 2016 | Last Updated: April 03, 2017
Study Completion Date: July 15, 2016
Learn More
A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris
The primary objective of this study is to evaluate the safety and efficacy of Omiganan (CLS001) topical gel compared to vehicle topical gel applied once daily for 12 weeks in female subjects with moderate to severe inflammatory acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: October 02, 2015 | Last Updated: March 24, 2017
Study Completion Date: August 31, 2016
Learn More
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
This is a single-blind (blinded expert grader) study that will enroll 25-30 healthy volunteers without facial acne. On 1 side of the face, the subject will apply 1 of the 2 test products, clindamycin and benzoyl peroxide 5% or clindamycin phosphate and benzoyl peroxide 2.5% and the other side of the face will remain non-treated to serve as a control.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: November 17, 2009 | Last Updated: March 21, 2017
Study Completion Date: September 30, 2009
Learn More
Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy
This study is being done to evaluate the effect of targeted UV-B (a component of sunlight) on the treatment of acne keloidalis nuchae (AKN, or razor bumps on the back of the neck). The investigators believe targeted UV-B is a safe and effective way to reduce the appearance of AKN.
Condition: Acne Keloidalis Nuchae |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: March 31, 2011 | Last Updated: February 28, 2017
Study Completion Date: August 31, 2012
Learn More
Performance of PicoWayTM Picosecond Fractional Laser for Acne Scars
Open-label, prospective study. Up to 60 healthy adult volunteers seeking facial acne scars treatment, males or females of 18 to 75 years of age, from up to 3 investigational sites.
Condition: Acne Scars - Mixed Atrophic and Hypertrophic |
Minimum Age: 18 Years
Status: Unknown status |
Phase: Not Applicable
First Posted: October 28, 2015 | Last Updated: February 22, 2017
Study Completion Date: August 31, 2017
Learn More
Apremilast in the Treatment of Moderate to Severe Acne
Acne is a chronic inflammatory disease of the pilosebaceous unit that affects 80-90% of the population, especially teenagers, although adult acne is a significant problem for 3-6 % of adult men and 5-12% of adult women. Although acne is not a life-threatening disease, it produces significant psychological disturbances and permanent skin scars.
A novel anti-inflammatory, not antibiotic drug may be an excellent alternative for the treatment of moderate to severe acne. Apremilast has been shown to inhibit the production of tumor necrosis factor (TNF)-alpha, IL-8 and neutrophil infiltration, all of which are elevated in inflammatory acne.
Our intention is to study Apremilast in the treatment of moderate to severe acne.
Condition: Acne |
Minimum Age: 18 Years
Status: Terminated |
Phase: Phase 2
First Posted: February 22, 2010 | Last Updated: February 01, 2017
Study Completion Date: October 31, 2010
Learn More
Impact of the M22-IPL Acne Filter on Acne Vulgaris
Up to 20 healthy subjects age 15-45 years old ,Skin Phototype I-V,Study will be conducted in 1 site.
Primary objectives is to evaluate the efficacy of IPL acne filter treatment for improvement of acne vulgaris as assessed by lesion count.
.
Condition: Acne |
Minimum Age: 15 Years
Status: Terminated |
Phase: Not Applicable
First Posted: July 01, 2014 | Last Updated: January 25, 2017
Study Completion Date: December 31, 2015
Learn More
Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne
Benzoyl peroxide, clindamycin and tazarotene are known to be effective treatment alternative for acne vulgaris. The purpose of this study is to assess the safety and efficacy of a combination product including these actives for the treatment of acne vulgaris.
You may be suitable to take part in this study because you have acne vulgaris on your face. Acne vulgaris usually affects the face, but it can also affect the skin on the chest, arms, legs, and back.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: July 07, 2008 | Last Updated: January 13, 2017
Study Completion Date: March 31, 2009
Learn More
Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris
Multi-center, double-blind, randomized, placebo-controlled trial of Dapsone 5.0% Gel in the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: July 01, 2016 | Last Updated: December 19, 2016
Study Completion Date: December 31, 2016
Learn More
A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris
A Randomized, Blinded, Single-Centered, Placebo-Controlled Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Withdrawn |
Phase: Phase 4
First Posted: December 31, 2015 | Last Updated: December 05, 2016
Study Completion Date: April 30, 2016
Learn More
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301
The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: November 19, 2009 | Last Updated: November 30, 2016
Study Completion Date: November 30, 2010
Learn More
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
The purpose of this study is to see if the investigators can prevent or reduce the severity of the Cetuximab-related acne rash. Two different topical agents will be applied to the skin. One topical agent is the dapsone gel and the other is a skin moisturizer. Dapsone gel is an FDA approved medication that you apply to the face. It is commonly used to treat acne. Skin moisturizers are recommended to patients who receive Cetuximab treatment. In addition to these topical agents they will be given a pill to take once a day. This pill has already been shown to help fight rashes from Cetuximab.
Condition: Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 3
First Posted: August 26, 2013 | Last Updated: November 18, 2016
Study Completion Date: September 30, 2015
Learn More
Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris
To compare the safety and efficacy profiles of Tazarotene Cream, 0.1 % to the reference listed drug Tazorac® (tazarotene) Cream, 0.1 % in order to demonstrate bioequivalence, and to demonstrate superiority of the 2 active creams over that of the cream vehicle (placebo) in the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: March 19, 2014 | Last Updated: November 02, 2016
Study Completion Date: July 31, 2015
Learn More
Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne
This is a Randomized, Double-Blind, Controlled Study to evaluate the Safety and Efficacy of a clindamycin / benzoyl peroxide gel in Subjects with Acne Vulgaris
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: October 21, 2008 | Last Updated: October 11, 2016
Study Completion Date: September 30, 2009
Learn More
A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne
Multi-center, single-blind, randomized, comparative, split-face study. The duration of the study is 8 weeks. Commencing at baseline, subjects will apply once daily both clindamycin and benzoyl peroxide gel and benzoyl peroxide/adapalene gel in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. After visit 3, subjects will commence application of clindamycin and benzoyl peroxide gel to the entire face for an additional 6 weeks.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: August 20, 2009 | Last Updated: October 11, 2016
Study Completion Date: November 30, 2009
Learn More
Non-cutting Laser Therapy in the Treatment of Acne
The purpose of this research project is to study the effect of non-ablative (non-cutting) laser therapy, a technique that uses laser energy to try to improve the appearance of the skin. This type of laser treatment creates changes in a layer of the skin called the dermis without causing an open wound in the skin. The use of non-ablative laser therapy, together with application of a photo-sensitizer (substance that makes the skin more sensitive to light), may improve the appearance of acne. The idea behind the photo-sensitizer is that it is supposed to make the laser more effective than using just the laser alone. It is not yet clear how much improvement can be seen with these treatments or exactly how the skin's response causes these improvements. In this study, we are interested in learning how well such a laser works to improve the symptoms of acne, as well as how much the photo-sensitizer actually enhances the efficacy of the laser.
Condition: Acne Vulgaris |
Minimum Age: 15 Years
Status: Completed |
Phase: Phase 2
First Posted: June 07, 2005 | Last Updated: August 22, 2016
Study Completion Date: November 30, 2008
Learn More
A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris
This study is designed to investigate the efficacy, safety and tolerability of MTC896 Gel in subjects with acne. In this study, MTC896 Gel will be applied at 3 concentrations, twice daily (bid) for 12 weeks and compared against a vehicle control.
Condition: Acne Vulgaris |
Minimum Age: 16 Years
Status: Unknown status |
Phase: Phase 2
First Posted: March 17, 2015 | Last Updated: June 14, 2016
Study Completion Date: August 31, 2016
Learn More
Microneedling Plus the Universal Peel For Acne Scarring
Acne is a prevalent disorder mostly witnessed in adolescents, but can be seen in adults. Early treatment is imperative to reduce acne scarring which can appear with atrophic lesions, and depending on the skin type, significant erythema (redness) or post-inflammatory hyperpigmentation. A multi-modality approach to treatment is necessary when dealing with the aforementioned types of lesions. Pharmacologic management is essential, but safe procedural therapies are also necessary specifically with darker skinned individuals.
Percutaneous collagen induction therapy (PCIT) is a non-invasive treatment achieved by using a micro-needling device, which is safe and effective in causing "micro-wounds" into the dermis thereby initiating wound healing followed by collagen production. This is an ideal treatment for acne scarring, re-texturizing of the skin, and hyperpigmentation for all skin types . Currently there are very few studies evaluating the safety and efficacy of microneedling and chemical peels in skin types III-VI.
The aim of this study is to evaluate the effects of the combination of microneedling and chemical peel for the treatment of acne scars in skin types III-VI.
Condition: Acne Scarring |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: June 20, 2014 | Last Updated: February 18, 2016
Study Completion Date: December 31, 2015
Learn More
Effect of Acne Vulgaris on Quality of Life of Teenagers Compared to Parent Perceived Effect on Quality of Life
Acne vulgaris is a common problem in the adolescent community. Past research has shown that acne affects teenager's self-esteem and mood. However, no research has evaluated the parent perception of their teenager's acne in comparison to the severity of acne and the patient's own reported quality of life. It is hypothesized that parents of teenagers underestimate how much acne vulgaris affects their teenager's skin disease-related quality of life. Also that teenager's perception of the severity of their acne is greater versus their parent's perception. We believe that increased acne severity based on clinician assessment will correlate with worse quality of life. Teenagers between 12 and 17 years old with a diagnosis of acne by a pediatric dermatologist will be enrolled in this study. The study consists of 1 visit, questions regarding demographics, assessment of the teen's acne, the Skindex-Teen quality of life survey (modified for parents), and 2 Likert scales will be completed. In addition, the clinician will score the teen's acne using the standardized Investigator Global Assessment tool. Statistical analysis will compare teen subject answers to the Skindex-Teen with their parent's answers. Also analyzed will be the severity of acne and differences between the clinician IGA score and Skindex-Teen responses
Condition: Acne, Quality of Life |
Minimum Age: 12 Years
Status: Completed |
Phase:
First Posted: April 16, 2013 | Last Updated: January 26, 2016
Study Completion Date: January 31, 2015
Learn More
Study of the Use of Low Level Laser Therapy to Reduce Acne
The purpose of this study is to determine whether low level laser light therapy is effective in the treatment of acne blemishes.
Condition: Acne |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: January 11, 2011 | Last Updated: November 07, 2015
Study Completion Date: June 30, 2010
Learn More
Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris
The primary objective of this study is to evaluate the safety and efficacy of once-daily topical application of CLS001 1%, 1.75% and 2.5% topical gel compared to vehicle topical gel in subjects with inflammatory acne vulgaris
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: February 18, 2014 | Last Updated: September 01, 2015
Study Completion Date: December 31, 1969
Learn More
Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study
The pilot study will investigate whether combination treatment of Finacea 15% Gel and Brimonidine 0.33% Gel could be more effective than Brimonidine 0.33% Gel monotherapy in treating both the papules/pustules and erythema associated with rosacea.
Condition: Acne Rosacea |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: May 16, 2014 | Last Updated: August 28, 2015
Study Completion Date: February 28, 2015
Learn More
A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris
This study will evaluate the effect of dapsone gel in female subjects with skin of color (Fitzpatrick Skin Types IV, V, and VI) with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: January 08, 2014 | Last Updated: August 11, 2015
Study Completion Date: September 30, 2014
Learn More
UVA1 Light for Scleroderma and Similar Conditions
The purpose of this investigation is to evaluate the effectiveness of high-dose UVA1 irradiation in the treatment of fibrosing conditions of the skin, e.g., keloid (a thick scar from growth of fibrous tissue), scleroderma (deposits of fibrous tissue in the skin) and acne keloidalis nuchae (keloids on the back of the neck or hairline) old burn scars, granuloma annulare or other similar skin conditions. This UVA1 dosing schedule has been used successfully in Germany for various skin diseases, such as the above mentioned scleroderma.
Condition: Acne Keloidalis Nuchae, Granuloma Annulare, Keloid, Scars, Scleroderma |
Minimum Age: 10 Years
Status: Terminated |
Phase: Not Applicable
First Posted: May 18, 2007 | Last Updated: July 24, 2015
Study Completion Date: July 31, 2003
Learn More
Microdermabrasion for Acne
The purpose of this research project is to study the effect of micordermabrasion to try to improve the appearance of facial acne. The microdermabrasion machine is a hand-held device that directs pressurized aluminum oxide crystals at its target accompanied by a suction device. It is not yet clear how much improvement can be seen with these treatments or exactly how the skin's response causes these improvements. In this study, we are interested in learning how well microdermabrasion works to improve the symptoms of acne.
Condition: Acne Vulgaris |
Minimum Age: 13 Years
Status: Completed |
Phase: Phase 2
First Posted: July 21, 2006 | Last Updated: July 08, 2015
Study Completion Date: July 31, 2007
Learn More
A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions
5 Day study to assess how quickly a topical acne product begins to work.
Condition: Skin Diseases |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: January 30, 2014 | Last Updated: May 14, 2015
Study Completion Date: May 31, 2014
Learn More
Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications
This is a single-blind (blinded expert grader), randomized, half-face study being conducted at one clinical site. On 1 side of the face, the subject will apply 1 of the 2 test products, antibiotic and benzoyl peroxide or benzoyl peroxide and adapalene gel and the contra lateral side of the face will remain non-treated to serve as a control. Approximately 25-30 male and female healthy subjects will be randomly assigned to each product
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: June 21, 2009 | Last Updated: May 01, 2015
Study Completion Date: July 31, 2009
Learn More
Infrared Non-Cutting Laser Therapy for Acne
The purpose of this research project is to study the effect of non-ablative (non-cutting) laser therapy, a technique that uses laser energy to try to improve the appearance of the skin. In this study, we are interested in learning how well such a laser works to improve the symptoms of acne. The laser used in this particular study will be the CoolTouch II® laser, manufactured by ICN Photonics, Inc., and has not been FDA-approved for the treatment of acne.
Condition: Acne Vulgaris |
Minimum Age: 13 Years
Status: Completed |
Phase: Phase 2/Phase 3
First Posted: May 11, 2005 | Last Updated: April 30, 2015
Study Completion Date: December 31, 2005
Learn More
Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix
This research study will evaluate the effectiveness of high dose UVB light therapy in the treatment of keloid (or hypertrophic scar), scleroderma, acne keloidalis nuchae, old burn scars, granuloma annulare or related conditions.
Condition: Acne Keloidalis, Granuloma Annulare, Keloid, Scars, Scleroderma, Localized |
Minimum Age: 10 Years
Status: Completed |
Phase: Phase 1/Phase 2
First Posted: August 09, 2005 | Last Updated: April 30, 2015
Study Completion Date: January 31, 2009
Learn More
Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris
This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 1
First Posted: August 14, 2014 | Last Updated: April 28, 2015
Study Completion Date: March 31, 2015
Learn More
Pharmacokinetic Study of MTC896 Gel in Subjects With Acne
The purpose of this study is to determine the pharmacokinetic properties of topically applied MTC896 Gel following application of 0.75% (w/w) MTC896 Gel once daily and twice daily and 1.5% (w/w) once daily over 4 weeks in the treatment of acne.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1/Phase 2
First Posted: November 11, 2014 | Last Updated: April 16, 2015
Study Completion Date: January 31, 2015
Learn More
Study of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris
This study is a split face, paired-comparison, pilot study of 10 subjects. Participants in this study will be patients seen at Children's Memorial Hospital, who are clinically diagnosed with mild to moderate acne vulgaris. Participants will be recruited from the clinic, as well as advertising and from previous Institutional Review Board (IRB) approved acne studies housed in the Department of Dermatology. All subjects accrued from previous studies have agreed to be contacted for further investigations. Subjects 13 to 35 years of age with mild to moderate acne vulgaris symmetrical in appearance on both sides of the face, and meeting inclusion criteria will be eligible to participate.
Condition: Acne Vulgaris |
Minimum Age: 13 Years
Status: Completed |
Phase: Not Applicable
First Posted: November 06, 2008 | Last Updated: April 10, 2015
Study Completion Date: January 31, 2009
Learn More
A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris
This study will identify how much (if any) drug is absorbed from the skin of subjects with acne vulgaris after topical application of SB204.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: June 12, 2014 | Last Updated: April 02, 2015
Study Completion Date: December 31, 2014
Learn More
Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel
This pilot study will explore if continuation of treatment of treatment with Aczone 5% gel following combination treatment with with doxycycline and Aczone 5% gel can maintain therapeutic response.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: June 21, 2013 | Last Updated: February 26, 2015
Study Completion Date: July 31, 2014
Learn More
Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone
This study will develop and evaluate the efficacy of an Internet-based education program incorporating virtual coaching. For this study, the virtual coach will consist of online videos aimed at providing acne education and promoting behaviors that support healthy skin. The use of Web-based technologies and virtual coaching in acne-related patient education is novel, and may significantly improve clinical outcomes and quality of life in acne patients. We hypothesize that an interactive Internet-based education and counseling program will be more effective than Internet-based education alone in improving clinical outcomes and quality of life in acne patients.
Condition: Acne Vulgaris |
Minimum Age: 13 Years
Status: Completed |
Phase: Not Applicable
First Posted: January 07, 2014 | Last Updated: February 26, 2015
Study Completion Date: July 31, 2014
Learn More
Musculoskeletal Effects of Isotretinoin During Acne Treatment in Pediatric Population
This is a prospective study, that will follow participants over their course of treatment on Isotretinoin. All patients who are prescribed Isotretinoin for their acne treatment are registered in iPLEDGE. The iPLEDGE program involves a set of steps that the patient, physician and pharmacist must follow for the patient to take Isotretinoin. Patients will be asked if they are willing to participate in this research study to determine musculoskeletal changes in adolescents and young adults on systemic therapy using the highly sensitive magnetic resonance (MR) imaging modality. In addition to the MRI, participants will be asked if they are willing to give an extra sample of blood when their routine blood work is being done for iPLEDGE. This blood sample will be used to determine if there are any effects of isotretinoin on bone turnover markers.
Condition: Acne |
Minimum Age: 12 Years
Status: Terminated |
Phase:
First Posted: August 21, 2009 | Last Updated: February 11, 2015
Study Completion Date: August 31, 2013
Learn More
BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris
The purpose of this study is to compare the safety and efficacy of BLI1100 formulations to placebo for the treatment of moderate to severe acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: March 18, 2013 | Last Updated: January 26, 2015
Study Completion Date: December 31, 1969
Learn More
Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.
The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles.
Condition: Acne Vulgaris |
Minimum Age: 14 Years
Status: Completed |
Phase: Phase 3
First Posted: March 31, 2008 | Last Updated: December 29, 2014
Study Completion Date: July 31, 2004
Learn More
Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne
The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles
Condition: Acne Vulgaris |
Minimum Age: 14 Years
Status: Completed |
Phase: Phase 3
First Posted: April 09, 2008 | Last Updated: December 29, 2014
Study Completion Date: June 30, 2004
Learn More
Topical 5-ALA-PDT With Blu-U Therapy Versus Topical 5-ALA With Pulse Dye Laser In Treating Recalcitrant Acne Vulgaris
The goal of this study is to compare how efficient two different types of PDTs are when used in combination with topical 5-ALA. The two types of PDT lights are Blu-U light and Candela V-beam Pulse Dye Laser.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Withdrawn |
Phase: Not Applicable
First Posted: December 23, 2008 | Last Updated: December 02, 2014
Study Completion Date: February 28, 2014
Learn More
Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo
The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.
Condition: Acne |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: May 28, 2010 | Last Updated: October 15, 2014
Study Completion Date: April 30, 2010
Learn More
Topical ASC-J9 Cream for Acne
To evaluate the safety and efficacy of topical 0.1% and 0.025% ASC-J9 creams applied twice daily for facial acne compared to vehicle control.
Condition: Acne |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: February 02, 2011 | Last Updated: July 29, 2014
Study Completion Date: August 31, 2012
Learn More
Comparison Study of Topical Acne Regimens
The purpose of this study is to compare the effectiveness of two over the counter acne products in subjects with moderate severity acne vulgaris. The two products being compared in this study are Acne Free "Severe Acne Line" manufactured by University Medical Products, and Proactiv® manufactured by Guthy-Renker.
Condition: Acne |
Minimum Age: 13 Years
Status: Completed |
Phase: Phase 4
First Posted: March 01, 2007 | Last Updated: June 23, 2014
Study Completion Date: February 29, 2008
Learn More
Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
The purpose of this study is to compare the efficacy and safety of CIP-Isotretinoin and a marketed (generic) formulation of isotretinoin when both are administered twice daily with meals.
Condition: Severe Nodular Acne |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: September 09, 2009 | Last Updated: June 05, 2014
Study Completion Date: May 31, 2011
Learn More
Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
Open, prospective, randomized, single-centre study in patients with moderate to severe facial acne vulgaris. Three circular areas with a diameter of 4 cm, each circle including at least 4 inflammatory lesions, will be selected in acne-affected areas in the face. One area should be identified on each cheek and one area should be identified on the forehead. The minimum distance between the three areas should be at least 4 cm. For each patient the three areas will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before application of the Visonac cream. One of the areas cleaned with saline wipe will also be occluded with a transparent dressing (Tegaderm) during the incubation time. In vivo fluorescence spectroscopy will be performed in the three areas before cream application, and at 1h, 1.5h, 2h, 2.5h and 3 h after cream application. After the last fluorescence spectroscopy reading, the cream should be wiped off and the patient should protect the three areas from sunlight, prolonged, or intense light for 2 days.
The study was extended with additionally 8 patients to explore the photoactive porphyrin levels over a 24 hour period:
The patients will clean their face with Cetaphil Gentle Skin Cleanser before cream application. For each patient the three areas will be randomized to Visonac 80mg left on the skin for 24 hours and Visonac (MAL8%) to be wiped of after 1 hour.
In vivo fluorescence spectroscopy will be performed at all three areas before cream application, and at 2h, 3 h, 4h, 5h, 8h, 10h, 11h, 12h, 13h, 15 and 24h after cream application. The exact time points may be adjusted based on the result from the previously included patients. All patients will be instructed to protect the three areas from sunlight, prolonged, or intense light for 2 days.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: July 08, 2010 | Last Updated: April 22, 2014
Study Completion Date: January 31, 2011
Learn More
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
The purpose of this study is to determine whether gevokizumab is effective in the treatment of moderate to severe acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 17 Years
Status: Completed |
Phase: Phase 2
First Posted: December 21, 2011 | Last Updated: March 03, 2014
Study Completion Date: June 30, 2013
Learn More
Effects of PRK 124 Lotion in Acne Rosacea
The purpose of this open-label study is to determine the tolerance and efficacy of twice-daily application of PRK 124 (Pyratine-6)(0.125%) moisturizing lotion for improving the signs and symptoms of mild to moderate facial rosacea.
Condition: Acne Rosacea |
Minimum Age: 21 Years
Status: Completed |
Phase: Phase 1/Phase 2
First Posted: December 21, 2007 | Last Updated: December 16, 2013
Study Completion Date: February 28, 2009
Learn More
Fractional Resurfacing Device for Treatment of Acne Scarring
The purpose of this research study is to evaluate the safety and effectiveness of a new investigational laser device for treatment of acne scarring, for improvement in the appearance of surface texture and topography (recessed or uneven surfaces).
Condition: Acne, Scar |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1/Phase 2
First Posted: December 26, 2007 | Last Updated: December 13, 2013
Study Completion Date: July 31, 2008
Learn More
A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris
This study is intended to evaluate the efficacy and safety of Visonac Photodynamic Therapy (PDT) in patients with severe acne, score 4 on global IGA scale. The null hypothesis is that Visonac PDT is equal to vehicle PDT against the alternative hypothesis that Visonac PDT is different compared to vehicle PDT at week 12.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: May 03, 2011 | Last Updated: December 02, 2013
Study Completion Date: May 31, 2012
Learn More
Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)
The purpose of this trial is to study the efficacy and safety of Visonac PDT in patients from 9 to 35 years old with Aktilite® CL512. Patients was randomized to Visonac or vehicle cream without occlusion and red light(dose: 37J/cm2)
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 2
First Posted: July 02, 2009 | Last Updated: November 15, 2013
Study Completion Date: March 31, 2010
Learn More
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne
This multicenter study will be divided into 2 phases. The first phase will be an open label, dose-escalation phase, while the second will be a blinded, randomized, vehicle-controlled, parallel-group, dose-response phase. The second phase will only start if the first phase succeeds in establishing well tolerated dose(s). Patients with moderate to severe acne vulgaris in the face will be included.The results from part 2 has been presented in the result section.
Condition: Acne Vulgaris |
Minimum Age: 15 Years
Status: Completed |
Phase: Phase 2
First Posted: January 03, 2008 | Last Updated: August 07, 2013
Study Completion Date: September 30, 2008
Learn More
Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring
The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM and placebo when administered to facial acne scars.
Condition: Acne Scarring of the Face |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2/Phase 3
First Posted: March 19, 2008 | Last Updated: July 19, 2013
Study Completion Date: March 31, 2009
Learn More
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
In this multicenter study, patients with dark skin and acne vulgaris will be included. The patients will receive treatment with MAL PDT and placebo PDT.
Condition: Acne Vulgaris |
Minimum Age: 15 Years
Status: Completed |
Phase: Phase 2
First Posted: May 05, 2008 | Last Updated: July 11, 2013
Study Completion Date: December 31, 2008
Learn More
Clinical Trial To Evaluate ANT-1207 In Subjects With Acne
The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of acne.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 2
First Posted: February 09, 2011 | Last Updated: June 28, 2013
Study Completion Date: July 31, 2012
Learn More
Epidermal Delivery of Ani-Aging Ingredients
To assess the safety and efficacy of an ablative fractional, 2940-nm laser combined with the US Impact and cosmetic -formulations for improving the appearance of wrinkles, acne scars and pigmented skin.
Condition: Acne Scars, Pigmentation, Wrinkles |
Minimum Age: 35 Years
Status: Unknown status |
Phase: Not Applicable
First Posted: May 02, 2013 | Last Updated: May 02, 2013
Study Completion Date: September 30, 2013
Learn More
Knowledge Evaluation and Assessment of the Effectiveness of an Education Intervention on Acne
Acne vulgaris is a chronic inflammatory disorder of the skin in the pilosebaceous unit of the hair follicle, associated with oil production. It is found across skin types and is present in 85% of adolescents, representing a large affected population. Because of the universal nature of the disease, 36.3% of acne patients come from backgrounds other than Caucasian.
The purpose of this study is to examine patient knowledge about acne in different populations and to assess the effectiveness of a teaching intervention on acne knowledge. The investigators aim is to better understand and subsequently reduce any potential health disparities within the minority populations.
This project will evaluate differences in acne knowledge between different ethnic groups, and the efficacy of an educational intervention. Subjects will first complete a survey evaluating their knowledge of acne and how acne affects them psychosocially before an educational intervention. Immediately following the intervention, the patient's knowledge of acne will be evaluated again. Finally, two months after the intervention, a phone call will be made evaluating their retention of the education materials and their quality of life related to psychosocial effects of acne. Investigating this educational intervention and any current disparities in acne education and understanding will better allow us to educate and treat acne patients in the future.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: June 26, 2012 | Last Updated: April 29, 2013
Study Completion Date: November 30, 2012
Learn More
Treatment of Moderate to Severe Facial Acne Vulgaris
Randomized, multi-center, double-blind, placebo-controlled 12-week study to assess the safety and efficacy of 3 doses of an oral formulation of Doxycycline oral tablets using the Investigator's Global Assessment (IGA) score and the absolute change from baseline in inflammatory lesion count in patients with moderate to severe facial acne vulgaris. Additionally, the absolute change from baseline in non-inflammatory and total lesions of the active study medication to placebo will be evaluated.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: January 25, 2008 | Last Updated: April 15, 2013
Study Completion Date: December 31, 2008
Learn More
NdYag Laser for Acne Keloidalis Nuchae
Acne Keloidalis Nuchae (AKN) is a long standing hair follicle disease with bumps and scars on the skin of the back of the head and neck. The purpose of this new study is to determine how well a hair removal laser (NdYag Laser) works in treating AKN.
Condition: Acne Keloid, Acne Keloidalis, Acne Keloidalis Nuchae, AK, AKN, Dermatitis Papillaris Capillitii, Folliculitis Keloidalis Nuchae, Folliculitis Nuchae Scleroticans, Keloidal Folliculitis, Lichen Keloidalis Nuchae, NdYag Laser, Sycosis Framboesiformis, Sycosis Nuchae |
Minimum Age: 18 Years
Status: Unknown status |
Phase: Not Applicable
First Posted: September 22, 2008 | Last Updated: March 27, 2013
Study Completion Date: December 31, 2013
Learn More
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
The purpose of this study is to find out if taking a birth control pill, YAZ, is safe and effective for treating acne on the trunk (the main part of the body that does not include the arms, legs, and head).
Acne vulgaris is a very common skin disorder. It is caused when oil-producing skin glands (sebaceous glands) become plugged. The plug can cause blackheads, whiteheads, pimples, and cysts on the face, neck, upper chest, and upper back.
YAZ is a combination birth control pill. A "combination" pill means that it is made up of more than one major ingredient. Nearly all birth control pills are made up of a combination of estrogen and progestin hormones. Estrogens are steroid hormones produced by the ovaries responsible for the typical female features. Progestins are steroid hormones produced by the ovary and placenta responsible for making the uterus fit for pregnancy. YAZ also contains an estrogen called ethinyl estradiol, and a progestin called drospirenone. People who develop acne have sebaceous glands that are over-stimulated (that is, the sebaceous glands have increased activity) by male sex hormones (androgens). The progestin in YAZ blocks the male sex hormones (androgens) that cause acne.
The study drug being used in this study is called YAZ. It has been approved by the U.S. Food and Drug Administration (FDA) to treat moderate acne in women who want an oral contraceptive for birth control.
In this study, YAZ will be compared to a placebo for safety and effectiveness. A placebo looks like the study drug but contains no active drug (like a sugar pill). We use placebos in research studies to learn if the effects seen in research subjects are truly from the study drug or from other reasons.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 3
First Posted: July 24, 2008 | Last Updated: January 29, 2013
Study Completion Date: April 30, 2012
Learn More
Effects of Acleara Needle Insert on Acne
This prospective, open-label study will be conducted in 15 healthy subjects per clinical site ages 14 or older who meet the inclusion/exclusion criteria. Each subject may have up to 5 lesions treated on the face, chest or back with the Acleara insert. Subjects will receive up to 3 follow up visits and evaluated for improvement in acne lesions and monitored for any adverse events.
Condition: Acne Vulgaris |
Minimum Age: 14 Years
Status: Completed |
Phase: Not Applicable
First Posted: August 29, 2012 | Last Updated: January 09, 2013
Study Completion Date: January 31, 2013
Learn More
Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System
The purpose of this study is to compare the results of treatment between the side of the face treated with the RevLite Laser and the side of the face treated with a fractionated laser system.
Condition: Acne Scars, Irregular Pigmentation, Photodamage |
Minimum Age: 25 Years
Status: Completed |
Phase: Not Applicable
First Posted: August 06, 2009 | Last Updated: November 27, 2012
Study Completion Date: February 29, 2012
Learn More
BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris
The purpose of this study is to compare the safety and efficacy of formulation BLI1100 to its vehicle in the treatment of moderate-severe acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: November 11, 2010 | Last Updated: September 27, 2012
Study Completion Date: December 31, 1969
Learn More
Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)
Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related to acne vulgaris. However, it has not been clinically tested for this purpose. The current study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris and PIH.
Condition: Acne Vulgaris, Post Inflammatory Hyperpigmentation |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: December 23, 2009 | Last Updated: August 24, 2012
Study Completion Date: May 31, 2010
Learn More
Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris
Comparison of the safety and efficacy of Tazarotene Cream 0.1% compared with Adapalene Gel 0.3% in treating moderate to severe facial acne vulgaris
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Terminated |
Phase: Phase 4
First Posted: January 22, 2009 | Last Updated: August 20, 2012
Study Completion Date: October 31, 2008
Learn More
Plant-based Dietary Intervention for Treatment of Acne
The purpose of this study is to determine if a low-fat, vegan diet affects the number of acne lesions, acne severity, and acne extent.
Condition: Acne |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: May 11, 2009 | Last Updated: August 06, 2012
Study Completion Date: March 31, 2010
Learn More
A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
A study comparing the topical application of Aczone® plus Differin® versus Duac® plus Differin® in patients with severe facial acne (facial acne vulgaris).
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: October 28, 2010 | Last Updated: June 25, 2012
Study Completion Date: June 30, 2011
Learn More
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
The purpose of this study is to evaluate the safety and efficacy of IDP-107 versus placebo in treating patients with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: September 01, 2010 | Last Updated: June 20, 2012
Study Completion Date: December 31, 2011
Learn More
Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne
This study will determine if the use of the BEAM device reduces the signs and symptoms of mild-to-moderate acne.
Condition: Acne |
Minimum Age: 15 Years
Status: Completed |
Phase: Not Applicable
First Posted: July 13, 2010 | Last Updated: May 01, 2012
Study Completion Date: October 31, 2010
Learn More
Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate
Randomized, multi-center, open label, active-comparator study to compare the efficacy and tolerability of Doryx Delayed Release Tablets to doxycycline hyclate in patients with moderate to severe acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: March 07, 2008 | Last Updated: April 18, 2012
Study Completion Date: September 30, 2008
Learn More
Evaluation of a Photopneumatic System for the Treatment of Acne
The purpose of the study is to evaluate the safety and efficacy of a photopneumatic therapy for the treatment of acne and concomitant symptoms associated with the disease, including erythema.
Condition: Mild to Moderate Acne |
Minimum Age: 18 Years
Status: Completed |
Phase:
First Posted: December 08, 2010 | Last Updated: March 22, 2012
Study Completion Date: September 30, 2011
Learn More
The Development and Evaluation of an "E-Visit" Program for the Management of Acne
The purpose of this study is to test the efficacy, timeliness, and user satisfaction of an online "E-Visit" application that uses store-and-forward technology for acne patients requiring dermatologic care for their condition. Hypotheses:
That an "E-Visit" is an effective alternative to in-person clinic care for patients with mild to severe facial acne.
That providers and patients will be satisfied with this model.
That mean wait times for new and return visits will be reduced through the "E-Visit" model.
That this prototype for care will improve clinic workflow, offer additional patient access, and allow urgent cases to be seen earlier.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Not Applicable
First Posted: December 29, 2006 | Last Updated: March 14, 2012
Study Completion Date: December 31, 2007
Learn More
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: April 23, 2008 | Last Updated: February 16, 2012
Study Completion Date: September 30, 2009
Learn More
Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.
A study to compare the skin irritation potential of two marketed gels for acne treatment, each applied to half of the face of healthy volunteers.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: July 10, 2008 | Last Updated: February 14, 2012
Study Completion Date: February 29, 2008
Learn More
A Study of Different Use Regimens Using Two Acne Treatments
A study to determine if using 2 acne products in the morning is as safe and efficacious as using one product in the morning and one product in the evening.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: May 20, 2009 | Last Updated: February 14, 2012
Study Completion Date: September 30, 2009
Learn More
A Study of Acne Treatment in Children Ages 9 to 11
A study to determine if using Retin-A Micro 0.04% as facial acne treatment in patients ages 9 to 11 is safe and efficacious.
Condition: Acne Vulgaris |
Minimum Age: 9 Years
Status: Completed |
Phase: Phase 2
First Posted: May 20, 2009 | Last Updated: February 14, 2012
Study Completion Date: December 31, 2009
Learn More
Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face
A study to compare the skin irritation potential of two marketed gels for acne treatment, each applied to half of the face of healthy volunteers.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: June 10, 2009 | Last Updated: February 14, 2012
Study Completion Date: May 31, 2009
Learn More
Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face
A study to compare the skin irritation potential of two marketed gels for acne treatment, each applied to half of the face of healthy volunteers.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: August 04, 2009 | Last Updated: February 14, 2012
Study Completion Date: October 31, 2009
Learn More
A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products
This study is to see if there's any difference in the amount of facial irritation when two acne products are used together on one side of the face, compared to one acne treatment product used alone on the other side of the face. All people participating in this trial will be required to return to the same study center every weekday for two weeks for the investigator to check for irritation on the face and to have the products applied - on weekends they will have to put them on at home. If one side of the face is more irritated than the other side, a picture will be taken as well.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 4
First Posted: March 10, 2011 | Last Updated: February 14, 2012
Study Completion Date: January 31, 2011
Learn More
A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris
EPIDUO™ (adapalene and benzoyl peroxide) Gel 0.1%/2.5%, marketed by GALDERMA LABORATORIES, L.P., is a safe and effective topical therapy used for the treatment of acne vulgaris. Actavis Mid-Atlantic LLC has developed a generic formulation of adapalene and benzoyl peroxide topical gel 0.1%/2.5%,and the current study is designed to evaluate the safety and efficacy of this formulation to determine if it is bioequivalent to EPIDUO™.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Not Applicable
First Posted: December 27, 2011 | Last Updated: December 28, 2011
Study Completion Date: December 31, 2011
Learn More
Combination Treatment for Moderate to Severe Acne
To determine if a combination of three currently approved acne products are safe and effective for the treatment of moderate to severe acne
Condition: Acne |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: September 17, 2010 | Last Updated: November 28, 2011
Study Completion Date: July 31, 2011
Learn More
A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris
The purpose of this study is to evaluate if topical ASC-J9 cream is effective in treating acne.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: August 31, 2007 | Last Updated: November 16, 2011
Study Completion Date: July 31, 2008
Learn More
Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne
The purpose of this study is to determine and compare the safety and efficacy of multiple broad area photodynamic therapy treatments with aminolevulinic acid (ALA-PDT) and vehicle (VEH-PDT) in subjects with moderate to severe facial acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 2
First Posted: June 24, 2008 | Last Updated: October 20, 2011
Study Completion Date: July 31, 2008
Learn More
Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris
The purpose of this study is to evaluate whether Cerave lotion followed by Acanya Gel in the morning in combination with Cerave lotion followed by Atralin gel in the evening is safe and effective for the treatment of acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Unknown status |
Phase: Phase 4
First Posted: October 05, 2011 | Last Updated: October 06, 2011
Study Completion Date: October 31, 2011
Learn More
Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris
A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tazarotene cream 0.1% compared with tazarotene cream 0.1% monotherapy in treating moderate to severe facial acne vulgaris
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: January 30, 2009 | Last Updated: September 22, 2011
Study Completion Date: September 30, 2009
Learn More
Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris
A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tretinoin gel 0.025% compared with tretinoin gel 0.025% monotherapy in treating moderate to severe facial acne vulgaris
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: January 30, 2009 | Last Updated: September 22, 2011
Study Completion Date: August 31, 2009
Learn More
A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne
There are many different factors that cause acne. So combination treatment using different medications that can address these different factors is commonly used to treat acne. Fixed-dose combination clindamycin phosphate 1.2% and tretinoin 0.025% gel and benzoyl peroxide 6% foaming cloths are both used to treat acne. This study will evaluate the use of the medications when used together.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Unknown status |
Phase: Phase 4
First Posted: August 12, 2011 | Last Updated: August 22, 2011
Study Completion Date: December 31, 1969
Learn More
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
This study is an evaluation of the role of topical dissolved oxygen to lessen visible signs of photodamage using a select regimen of topical dissolved oxygen containing cosmeceutical products. Evaluation of the overall skin tolerability of topical dissolved oxygen (safety) utilizing the regimen of products.
Condition: Acne Vulgaris, Atopic Dermatitis, Rosacea, Seborrheic Dermatitis |
Minimum Age: 25 Years
Status: Completed |
Phase: Phase 2
First Posted: October 06, 2009 | Last Updated: June 06, 2011
Study Completion Date: January 31, 2010
Learn More
Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency
The purpose of this study is to gather more information about the safety of ACZONE Gel, 5% in treating subjects with acne who have certain blood disorders.
ACZONE Gel, 5% is a prescription skin use (topical) medicine used to help treat acne in people 12 years and older. ACZONE Gel, 5% has been studied in approximately 4000 people and was shown to reduce the number of pimples and improve acne.
The active drug ingredient in ACZONE Gel, 5% is dapsone. People with blood disorders called "G6PD deficiency", "methemoglobin reductase deficiency", and "hemoglobin M" have a higher chance of side effects with dapsone.
G6PD is short for "glucose-6-phosphate dehydrogenase". It is an enzyme found in red blood cells, which carry oxygen to all parts of the body. G6PD helps the red blood cells to function normally. Some people have less G6PD in their red blood cells than the average person. This is called G6PD deficiency.
Two treatments - ACZONE Gel, 5% and placebo - will be studied for comparison.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: October 21, 2005 | Last Updated: May 27, 2011
Study Completion Date: October 31, 2006
Learn More
A Novel Combination Oral Agent to Treat Acne Vulgaris
The purpose of this study is to evaluate a novel, combination product for the treatment of acne vulgaris in females
Condition: ACNE VULGARIS |
Minimum Age: 13 Years
Status: Unknown status |
Phase: Phase 1/Phase 2
First Posted: February 16, 2011 | Last Updated: February 18, 2011
Study Completion Date: September 30, 2011
Learn More
Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris
The objective of this study was to evaluate the efficacy and safety of the test formulation of adapalene gel 0.1% (PLIVA Research & Development Ltd.) as compared to the already marketed formulation, Differin® (adapalene 0.1%) topical gel (Galderma Laboratories) in patients with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 1
First Posted: August 13, 2010 | Last Updated: November 22, 2010
Study Completion Date: April 30, 2008
Learn More
A Study to Determine the Safety and Efficacy of an Ultrasound Device in the Management of Acute Acne Lesions
The purpose of this study is to find out how effective and safe an experimental ultrasound device is for treating Acute Acne lesions.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 1
First Posted: July 09, 2010 | Last Updated: July 09, 2010
Study Completion Date: December 31, 1969
Learn More
Efficacy & Safety of Clindamycin and Tretinoin in Acne
The purpose of this study is ascertain the efficacy and safety of Clindamycin
Phosphate 1.2% and Tretinoin 0.025% in the treatment of Acne and Post
Inflammatory Hyperpigmentation in patients with skin of color.
Condition: Acne |
Minimum Age: 12 Years
Status: Unknown status |
Phase: Phase 4
First Posted: April 26, 2010 | Last Updated: May 19, 2010
Study Completion Date: April 30, 2010
Learn More
5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris
12-week study to compare the efficacy and safety of a course of a twice daily treatment with APS in the form of a lotion to its vehicle for the treatment of acne.
Condition: Acne Vulgaris |
Minimum Age: 18 Years
Status: Completed |
Phase: Not Applicable
First Posted: July 03, 2008 | Last Updated: July 11, 2008
Study Completion Date: December 31, 1969
Learn More
A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: April 15, 2008 | Last Updated: April 18, 2008
Study Completion Date: December 31, 1969
Learn More
A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with acne vulgaris.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 3
First Posted: April 15, 2008 | Last Updated: April 18, 2008
Study Completion Date: December 31, 1969
Learn More
Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris
Tissue inflammation is a major component of the acne disease process. Leukotriene B4 (LTB4) is thought to be a major player in the development of tissue inflammation. Synthesis of LTB4 is controlled by the enzyme 5-lipoxygenase. Zileuton blocks the activity of 5-lipoxygenase. This study will test the safety and efficacy of zileuton in the treatment of facial acne.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Unknown status |
Phase: Phase 2
First Posted: December 07, 2004 | Last Updated: February 05, 2007
Study Completion Date: May 31, 2005
Learn More
NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®
Food allergy reactions cause various health disorders in sensitive people. These reactions may be IgE-mediated,cell-mediated, energy disturbance-mediated, or a combination of the three. Certain laboratory diagnostic procedures have been able to identify most IgE-mediated or cell-mediated food reactions, but so far there is no test available in traditional medicine to test the energy-mediated allergies and sensitivities. NAET® procedures have been able to identify food substances triggering to energ disturbances in sensitive people causing related health disorders. NAET uses one of the testing procedures called NST (Neuromuscular sensitivity testing).The efficacy of NST-NAET to screen food sensitivity will be evaluated in comparison with one of the well accepted, established, traditional medicine allergy testing known as the IgE-specific antigen test.
Condition: Backache, Eczema, Acne, Hives and Itching of the Skin, Food Sensitivities, Headache, Indigestion |
Minimum Age: 2 Years
Status: Completed |
Phase:
First Posted: January 10, 2006 | Last Updated: October 31, 2006
Study Completion Date: January 31, 2006
Learn More
Comparison of Stacked-Pulses Vs. Double-Pass Treatments of Facial Acne With a 1450 Nm Laser
Acne can be treated with a mid-infrared laser. We demonstrated safety and efficacy using lower energy settings in order to make the treatments less painful
Condition: Acne, Acne Scars |
Minimum Age: 18 Years
Status: Completed |
Phase:
First Posted: March 22, 2006 | Last Updated: March 22, 2006
Study Completion Date: February 28, 2006
Learn More
Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris
The purpose of the study is to compare the efficacy of three maintenance regimens (topical tazarotene, oral minocycline, or both) in sustaining improvement in acne.
Condition: Acne Vulgaris |
Minimum Age: 12 Years
Status: Completed |
Phase: Phase 4
First Posted: September 01, 2005 | Last Updated: December 14, 2005
Study Completion Date: August 31, 2002
Learn More
Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea
The purpose of this study is to determine whether Periostat(R), Doxycycline Hyclate 20 mg Tablets, taken twice daily is effective in reducing the red and white heads and overall redness associated with rosacea.
Condition: Acne Rosacea |
Minimum Age: 18 Years
Status: Completed |
Phase: Phase 3
First Posted: July 19, 2002 | Last Updated: June 23, 2005
Study Completion Date: December 31, 1969
Learn More
